



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 145634

TO: Jennifer Kim
Location: 4b02 / 4b18
Wednesday, February 23, 2005
Art Unit: 1617
Phone: 272-0628
Serial Number: 10 / 029424

From: Jan Delaval
Location: Biotech-Chem Library
Rem 1a51
Phone: 272-2504

jan.delaval@uspto.gov

Search Notes

Jan Deleva

Access DB# 145634

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name

Jennifer Kim

Examiner #

77469

Date: 2/18/05

Ant#

1617

Phone Number

3X20628

Serial Number

10/029,424

Mail Box and Bldg Room Location

4B02

Remsen

Results Format Preferred (circle)

PAPER

DISK

E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic and describe as specifically as possible the subject matter to be searched. Include the element species or structures, keywords, synonyms, acronyms and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention

Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy

Inventors (please provide full names)

Leonard et al.

Earliest Priority Filing Date

12/22/2000

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number

1) Please search claim 32

2) Please display structures + registry # of the cpd 1-10 in claim 32. (Please # each cpd as 1-10)

THX,

JM

STAFF USE ONLY

Searcher

Jan

Type of Search

NA Sequence (#)

Vendors and cost where applicable

STN

Searcher Phone #

22504

AA Sequence (#)

Dialog

Searcher Location

2123105

Structure (#)

Quest

Date Entered

2/23/05

Bio-logicals

+

Date Entered

2/23/05

Litigation

+

Searcher Prep & Ref. #

15

Full Text

Sequence Systems

Searcher Prep & Ref. #

15

Patent Family

AA Images

Searcher Prep & Ref. #

15

Other

Image Search

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:44:50 ON 23 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2005 HIGHEST RN 835870-69-4
DICTIONARY FILE UPDATES: 22 FEB 2005 HIGHEST RN 835870-69-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide can 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 53-16-7 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estrone (8CI)
OTHER NAMES:
CN (+)-Estrone
CN Δ1,3,5(10)-Estratrien-3-ol-17-one
CN 1,3,5(10)-Estratrien-3-ol-17-one
CN 3-Hydroxy-17-keto-estra-1,3,5-triene
CN 3-Hydroxyestra-1,3,5(10)-trien-17-one
CN 3-Hydroxyestra-1,3,5(10)-triene-17-one
CN 3-Hydroxyoestra-1,3,5(10)-trien-17-one
CN Aquacrine
CN Crinovaryl
CN Cristallovar
CN Crystogen
CN Destrone
CN Disynformon
CN Endofolliculina
CN Estron
CN Estrovarin
CN Estrugenone
CN Estrusol
CN Femestrone Inj.
CN Femestrone injection
CN Femidyn
CN Fermidyn
CN Folikrin
CN Folipex
CN Folisan
CN Follestrine
CN Follestrol
CN Follicular hormone
CN Folliculin
CN Folliculin (steroid)
CN Follicunodis

CN Follidrin
 CN Glandubolin
 CN Hiestrone
 CN Hormofollin
 CN Hormovarine
 CN Kestrone
 CN Ketodestrin
 CN Keto hydroxyestrin
 CN Kolpon
 CN Menagen
 CN Menformon
 CN NSC 9699
 CN Oestrin
 CN Oestroform
 CN Oestrone
 CN Oestropelos
 CN Ovifollin
 CN Perlatan

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH
 DR 37242-41-4
 MF C18 H22 O2
 CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
 DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT,
 IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT,
 PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2,
 USPATFULL, VETU


(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent; Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
 PROC (Process); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10760 REFERENCES IN FILE CA (1907 TO DATE)
 259 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 10766 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:162670
 REFERENCE 2: 142:162271
 REFERENCE 3: 142:162267
 REFERENCE 4: 142:156210
 REFERENCE 5: 142:156209
 REFERENCE 6: 142:153029
 REFERENCE 7: 142:134783
 REFERENCE 8: 142:134175
 REFERENCE 9: 142:133675
 REFERENCE 10: 142:127738

=> d ide can 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 474-86-2 REGISTRY
 CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Equilin (6CI, 7CI)
 OTHER NAMES:
 CN 1,3,5,7-Estratetraen-3-ol-17-one
 CN 3-Hydroxyestra-1,3,5(10),7-tetraen-17-one
 CN 7-Dehydroestrone
 CN NSC 10971
 FS STEREOSEARCH
 MF C18 H20 O2
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
 CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXCENTER,
 USAN, USPAT2, USPATFULL


(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Cplus document type: Conference; Dissertation; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
 RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
 USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
 (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
 reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

436 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 438 REFERENCES IN FILE CPLUS (1907 TO DATE)
 41 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:70104
 REFERENCE 2: 142:33812
 REFERENCE 3: 141:360695
 REFERENCE 4: 141:344068
 REFERENCE 5: 141:343686
 REFERENCE 6: 141:314487
 REFERENCE 7: 141:248468
 REFERENCE 8: 141:154709
 REFERENCE 9: 141:94343
 REFERENCE 10: 141:33322

=> d ide can 17

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX
NAME)

OTHER NAMES:

CN Δ^8 ,9-Dehydroestrone

CN Δ^8 -Dehydroestrone

CN Δ^8 -Isoequilin

CN 8,9-Dehydroestrone

FS STEREOSEARCH

MF C18 H20 O2

LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER,
USPATFULL

(*File contains numerically searchable property data)

DT.CA CAplus document type: Conference; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); PREP (Preparation); PROC (Process); PRP (Properties); USES
(Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

49 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

49 REFERENCES IN FILE CAPLUS (1907 TO DATE)

4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695

REFERENCE 2: 141:344068

REFERENCE 3: 141:314487

REFERENCE 4: 141:94343

REFERENCE 5: 141:1503

REFERENCE 6: 139:396107

REFERENCE 7: 139:375242

REFERENCE 8: 139:302513


REFERENCE 9: 139:281289

REFERENCE 10: 139:271455

> d ide can 18

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 57-91-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 17 α -Estradiol (8CI)
OTHER NAMES:
CN α -Estradiol
CN 1,3,5-Estratriene-3,17 α -diol
CN 13 β -Methyl-1,3,5(10)-gonatriene-3,17 α -diol
CN 17-Epiestradiol
CN 17 α -Oestradiol
CN 3,17-Dihydroxyestratriene
CN 3,17 α -Dihydroxyestra-1,3,5(10)-triene
CN 3,17 α -Dihydroxyoestra-1,3,5(10)-triene
CN Alfatradiol
CN Epiestradiol
CN Epiestrol
CN Estra-1,3,5(10)-triene-3,17 α -diol
CN NSC 20293
CN Oestra-1,3,5(10)-triene-3,17 α -diol
FS STEREOSEARCH
MF C18 H24 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1269 REFERENCES IN FILE CA (1907 TO DATE)
 33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1270 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:127686
 REFERENCE 2: 142:107663
 REFERENCE 3: 142:70007
 REFERENCE 4: 142:69327
 REFERENCE 5: 142:68505
 REFERENCE 6: 142:49386
 REFERENCE 7: 142:49373
 REFERENCE 8: 142:49360
 REFERENCE 9: 142:33812
 REFERENCE 10: 142:27729


=> d ide can 19

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 3563-27-7 REGISTRY
 CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Estra-1,3,5(10),7-tetraene-3,17 β -diol (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN β -Dihydroequilin
 CN 17 β -Dihydroequilin
 CN 7-Dehydroestradiol
 CN NSC 12170
 FS STEREOSEARCH
 MF C18 H22 O2
 CI COM
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
 CAOLD, CAPLUS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT,
 IFIUDB, MRCK*, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Cplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

109 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 109 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695
 REFERENCE 2: 141:314487
 REFERENCE 3: 141:94343
 REFERENCE 4: 141:1503
 REFERENCE 5: 140:363029
 REFERENCE 6: 139:375242
 REFERENCE 7: 139:302513
 REFERENCE 8: 139:281289
 REFERENCE 9: 139:271455
 REFERENCE 10: 139:224682

=> d ide can 110

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 651-55-8 REGISTRY
 CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17alpha)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Estra-1,3,5(10),7-tetraene-3,17alpha-diol (8CI)

OTHER NAMES:


CN α -Dihydroequilin
 CN α -Equilol
 CN 17 α -Dihydroequilin
 FS STEREOSEARCH
 MF C18 H22 O2
 CI COM
 LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CHEMLIST, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB,
 MEDLINE, MRCK*, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Conference; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
 RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
 (Preparation); PROC (Process); PRP (Properties); USES (Uses); NORL (No
 role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); FORM (Formation, nonpreparative)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

104 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 105 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:360695
 REFERENCE 2: 141:314487
 REFERENCE 3: 141:94343
 REFERENCE 4: 141:1503
 REFERENCE 5: 140:139705
 REFERENCE 6: 139:375242
 REFERENCE 7: 139:302513
 REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:57888

> d ide can 111

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 50-28-2 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estradiol (8CI)
OTHER NAMES:
CN (+)-3,17 β -Estradiol
CN β -Estradiol
CN 13 β -Methyl-1,3,5(10)-gonatriene-3,17 β -ol
CN 17 β -Estradiol
CN 17 β -Oestradiol
CN 3,17-Epidihydroxyestratriene
CN 3,17 β -Dihydroxyestra-1,3,5(10)-triene
CN 3,17 β -Estradiol
CN Absorlent Matrix
CN Aeradiol
CN Altrad
CN Aquadiol
CN Bardiol
CN Beta-estradiol
CN Climaderm
CN Climara
CN Compudose
CN Compudose 200
CN Compudose 365
CN Corpagen
CN Dermestril
CN Dihydrofollicular hormone
CN Dihydrofolliculin
CN Dihydromenformon
CN Dihydrotheelin
CN Dihydroxyestrin
CN Dimenformon
CN Diogyn
CN Diogynets
CN Divigel
CN E 2
CN Encore
CN Epiestriol 50
CN Estra-1,3,5(10)-triene-3,17-diol, (17 β) -
CN Estra-1,3,5(10)-triene-3,17 β -diol
CN Estrace
CN Estraderm
CN Estraderm TTS
CN Estraderm TTS 100
CN Estraderm TTS 50
CN Estradot
CN Estraldine
CN Estring Vaginal Ring
CN Estroclim
CN Estroclim 50
CN Estrogel
CN Estrogel HBF
CN Estrovite
CN Evorel

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY

FS STEREOSEARCH

MF C18 H24 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

54116 REFERENCES IN FILE CA (1907 TO DATE)

983 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

54182 REFERENCES IN FILE CAPLUS (1907 TO DATE)

12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:162670

REFERENCE 2: 142:162267

REFERENCE 3: 142:162088


REFERENCE 4: 142:156210

REFERENCE 5: 142:156209
REFERENCE 6: 142:154840
REFERENCE 7: 142:153320
REFERENCE 8: 142:153270
REFERENCE 9: 142:153168
REFERENCE 10: 142:153029

=> d ide can 112

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 517-09-9 REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Equilenin (6CI)
OTHER NAMES:
CN (+)-Equilenin
CN 3-Hydroxyestra-1,3,5(10),6,8-pentaen-17-one
CN d-Equilenin
CN Equilenine
CN NSC 9901
FS STEREOSEARCH
MF C18 H18 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB,
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, RTECS*, SPECINFO,
TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

483 REFERENCES IN FILE CA (1907 TO DATE)
 23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 484 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 29 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:93155
 REFERENCE 2: 142:33812
 REFERENCE 3: 141:389284
 REFERENCE 4: 141:383841
 REFERENCE 5: 141:380063
 REFERENCE 6: 141:360695
 REFERENCE 7: 141:343686
 REFERENCE 8: 141:314487
 REFERENCE 9: 141:154709
 REFERENCE 10: 141:94343


=> d ide can 113

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 6639-99-2 REGISTRY
 CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Estra-1,3,5(10),6,8-pentaene-3,17 α -diol (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN α -Dihydroequilenin
 CN 17 α -Dihydroequilenin
 CN Estra-1,3,5,7,9-pentaene-3,17 α -diol
 CN NSC 12171
 FS STEREOSEARCH
 DR 73088-21-8
 MF C18 H20 O2
 CI COM
 LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CHEMLIST,
 DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS, RTECS*, TOXCENTER,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Cplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); FORM (Formation, nonpreparative)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 103 REFERENCES IN FILE CPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695
 REFERENCE 2: 141:314487
 REFERENCE 3: 141:94343
 REFERENCE 4: 141:1503
 REFERENCE 5: 140:157620
 REFERENCE 6: 139:375242
 REFERENCE 7: 139:302513
 REFERENCE 8: 139:281289
 REFERENCE 9: 139:271455
 REFERENCE 10: 139:57888

=> d ide can 114

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 1423-97-8 REGISTRY
 CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:

CN Estra-1,3,5(10),6,8-pentaene-3,17 β -diol (6CI, 7CI)
 CN Estra-1,3,5,7,9-pentaene-3,17 β -diol (8CI)

OTHER NAMES:

CN β -Dihydroequilenin
 CN 17 β -Dihydroequilenin
 FS STEREOSEARCH
 MF C18 H20 O2
 CI COM

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD,
 CAPLUS, CHEMLIST, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, MEDLINE,
 MSDS-OHS, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Conference; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

105 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 105 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:314487

REFERENCE 2: 141:94343

REFERENCE 3: 141:65339

REFERENCE 4: 141:1503

REFERENCE 5: 140:157620

REFERENCE 6: 139:375242

REFERENCE 7: 139:302513

REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:79288

>=> d ide can 117

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 53-39-4 REGISTRY

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Oxa-5 α -androstan-3-one, 17 β -hydroxy-17-methyl- (7CI, 8CI)CN 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5 α ,17 β)-

OTHER NAMES:

CN 17-Methyl-2-oxa-5 α -androstan-17 β -ol-3-oneCN 17 β -Hydroxy-17-methyl-2-oxa-5 α -androstan-3-oneCN 17 β -Hydroxy-17 α -methyl-2-oxa-5 α -androstan-3-one

CN 8075CB

CN Anavar

CN Lonavar

CN NSC 67068

CN Oxandren

CN Oxandrin

CN Oxandrolone

CN Protivar

CN Provistar

CN SC 11585

CN Vasorome

FS STEREOSEARCH

MF C19 H30 O3

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

268 REFERENCES IN FILE CA (1907 TO DATE)
 11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 268 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 142:141282
 REFERENCE 2: 142:120512
 REFERENCE 3: 142:86805
 REFERENCE 4: 142:32284
 REFERENCE 5: 141:388999
 REFERENCE 6: 141:375642
 REFERENCE 7: 141:332356
 REFERENCE 8: 141:325783
 REFERENCE 9: 141:313434
 REFERENCE 10: 141:308745

=> d ide can 118

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 434-07-1 REGISTRY
 CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-,
 (5 α ,17 β)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 5 α -Androstan-3-one, 17 β -hydroxy-2-(hydroxymethylene)-17-methyl-
 (6CI, 8CI)
 OTHER NAMES:
 CN 17-Beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone
 CN 17 α -Methyl-2-hydroxymethylene-17-hydroxy-5 α -androstan-3-one
 CN 17 β -Hydroxy-2-(hydroxymethylene)-17-methyl-5 α -androstan-3-one
 CN 17 β -Hydroxy-2-(hydroxymethylene)-17 α -methyl-5 α -androstan-
 3-one
 CN 2-(Hydroxymethylene)-17-methyldihydrotestosterone
 CN 2-Hydroxymethylene-17 α -methyl-17 β -hydroxy-3-androstanone
 CN 2-Hydroxymethylene-17 α -methylandrostan-17 β -ol-3-one
 CN 2-Hydroxymethylene-17 β -hydroxy-17 α -methyl-5 α -androstan-3-
 one

CN Adroyd
CN Anadrol
CN Anapolan 50
CN Anapolon
CN Anasteron
CN Anasteronal
CN Anasterone
CN Becorel
CN C.I. 406
CN HMD
CN Nastenon
CN NSC-26198
CN Oxymethenolone
CN Oxymetholone
CN Pardroyd
CN Plenastril
CN Prostanabol
CN Roboral
CN Synasteron
CN Synasteron 50
FS STEREOSEARCH
MF C21 H32 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU,
EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*,
MSDS-OHS, NIOSHTIC, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN,
USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses);
NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study)

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

338 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 338 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 142:149880
 REFERENCE 2: 142:120512
 REFERENCE 3: 142:86805
 REFERENCE 4: 141:390068
 REFERENCE 5: 141:388923
 REFERENCE 6: 141:282811
 REFERENCE 7: 141:135530
 REFERENCE 8: 141:42919
 REFERENCE 9: 141:28671
 REFERENCE 10: 140:193319

=> d ide can 119

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 10418-03-8 REGISTRY
 CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)-
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2'H-5 α -Androst-2-eno[3,2-c]pyrazol-17 β -ol, 17-methyl- (8CI)
 CN Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol,
 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-
 trimethyl- (6CI, 7CI)
 CN Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-
 17-ol deriv.
 OTHER NAMES:
 CN 17-Methyl-5 α -androstano[3,2-c]pyrazol-17 β -ol
 CN 17-Methyl-pyrazolo[4',3':2,3]-5 α -androstan-17 β -ol
 CN 17 α -Methyl-17 β -hydroxy-5 α -androstano[3,2-c]pyrazole
 CN 17 β -Hydroxy-17-methyl-5 α -androstano[3,2-c]pyrazole
 CN 17 β -Hydroxy-17 α -methyl-5 α -androstano[3,2-c]pyrazole
 CN Anabol
 CN Androstanazol
 CN Androstanazole
 CN Androstanazolestanazol
 CN Estazol
 CN NSC 233046
 CN NSC 43193
 CN Stanazolol
 CN Stanozolol
 CN Stromba
 CN Strombaject
 CN Tevabolin
 CN Win 14833
 CN Winstroid
 CN Winstrol
 CN Winstrol Depot

CN Winstrol V
 AR 302-96-5
 FS STEREOSEARCH
 DR 17966-55-1, 69353-49-7
 MF C21 H32 N2 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IPA, MEDLINE, MRCK*,
 PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in
 record)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in
 record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); PRP
 (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

428 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE	1:	142:120512
REFERENCE	2:	142:86805
REFERENCE	3:	142:69995
REFERENCE	4:	141:420535
REFERENCE	5:	141:308751
REFERENCE	6:	141:308745

REFERENCE 7: 141:282811

REFERENCE 8: 141:236865

REFERENCE 9: 141:220275

REFERENCE 10: 141:212833

=> d ide can 120

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 17230-88-5 REGISTRY

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 17 α -Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol (8CI)

CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol, 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl- (7CI)

CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazole, pregnna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol deriv.

OTHER NAMES:

CN 17 α -Pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17 β -ol

CN Bonzol

CN Chronogyn

CN Cyclomen

CN Danazol

CN Danazolum

CN Danocrine

CN Danol

CN Danovaol

CN Danzol

CN Ladogal

CN NSC 270916

CN Win 17757

CN Winobanin

FS STEREOSEARCH

MF C22 H27 N O2

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Conference; Dissertation; Journal; Patent


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

658 REFERENCES IN FILE CA (1907 TO DATE)
 13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 659 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:127711
 REFERENCE 2: 142:120512
 REFERENCE 3: 142:120319
 REFERENCE 4: 142:107349
 REFERENCE 5: 142:106811
 REFERENCE 6: 142:28161
 REFERENCE 7: 142:16869
 REFERENCE 8: 142:11382
 REFERENCE 9: 142:11380
 REFERENCE 10: 141:388765

=> fil hcplus
 FILE 'HCPLUS' ENTERED AT 15:46:15 ON 23 FEB 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2005 VOL 142 ISS 9
 FILE LAST UPDATED: 22 Feb 2005 (20050222/ED)

This file contains CAS Registry Numbers for easy and accurate

12/22/2000

substance identification.

=> d all hitstr tot 160

L60 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:818295 HCAPLUS
 DN 139:302513
 ED Entered STN: 17 Oct 2003
 TI Hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause
 IN Leonard, Thomas W.; Waldon, R. Forrest
 PA Endeavor Pharmaceuticals, USA
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-56
 CC 2-4 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084547	A1	20031016	WO 2003-US2873	20030131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003216366	A1	20031120	US 2003-356242	20030131
	EP 1494679	A1	20050112	EP 2003-746025	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-369905P	P	20020403		
	WO 2003-US2873	W	20030131		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2003084547	ICM	A61K031-56
AB	The present invention includes methods for treating vasomotor symptoms associated with human menopause through the administration of estrogenic compds. The methods presented may include starting estrogen therapy at a high dose, and then lowering the dose once therapy has been shown to be effective. Progestins and androgenic compound can addnl. be combined with the therapy.		
ST	estrogen hormone replacement therapy menopause disorder vasomotor symptom		
IT	Estrogens RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (conjugated; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)		
IT	Menopause (disorder, hot flash; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)		
IT	Menopause (disorder; hormone replacement		

therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Skin, disease
 (dry; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Hair, disease
 Vagina, disease
 (dryness; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Bladder, disease
 Drug delivery systems
 Hormone replacement therapy
 Human
 Insomnia
 (hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Estrogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Androgens
 Progestogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in conjunction with estrogen replacement therapy; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT Mental disorder
 (mood-affecting; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT 50-28-2, 17 β -Estradiol,
 biological studies 53-16-7, Estrone, biological studies 57-63-6, Ethinyl estradiol 57-91-0,
 17 α -Estradiol 474-86-2,
 Equilin 474-87-3, Δ 8,9-Dehydroestrone
 517-09-9, Equilenin 651-55-8, 17 α -Dihydroequilin 979-32-8, Estradiol valerate 1423-97-8, 17 β -Dihydroequilin 3563-27-7, 17 β -Dihydroequilin 6639-99-2, 17 α -Dihydroequilin 23392-54-3, 17 β - Δ 8,9-Dehydroestradiol 162707-56-4, 17 α - Δ 8,9-Dehydroestradiol 360792-45-6, 6-Hydroxy-17 β -dihydroequilin 360792-47-8, 6-Hydroxyequilenin 360796-54-9, 6-Hydroxy-17 α -dihydroequilin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

IT 53-39-4, Oxandrolone 434-07-1,
 Oxymetholone 521-18-6, Stanolone 10418-03-8,
 Stanozolol 17230-88-5, Danazol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in conjunction with estrogen replacement

therapy; hormone replacement

therapy with estrogenic compound to treat vasomotor symptoms associated with menopause)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Hirvonen; US 5043331 A 1991 HCAPLUS

(2) Plunkett; US 36247 A 1999 HCAPLUS

IT 50-28-2, 17 β -Estradiol,

biological studies 53-16-7, Estrone, biological studies 57-91-0, 17 α -Estradiol

474-86-2, Equilin 474-87-3,

Δ 8,9-Dehydroestrone 517-09-9, Equilenin 651-55-8

, 17 α -Dihydroequilin 1423-97-8

, 17 β -Dihydroequilenin

3563-27-7, 17 β -Dihydroequilin

6639-99-2, 17 α -Dihydroequilenin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(hormone replacement therapy with

estrogenic compound to treat vasomotor symptoms associated with menopause)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 57-91-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-86-2 HCPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

IT 53-39-4, Oxandrolone 434-07-1,
Oxymetholone 10418-03-8, Stanozolol
17230-88-5, DanazolRL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(in conjunction with estrogen replacement
therapy; hormone replacement
therapy with estrogenic compound to treat vasomotor symptoms
associated with menopause)

RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-,
(5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 10418-03-8 HCAPLUS
 CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
 CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:796313 HCAPLUS
 DN 139:271455
 ED Entered STN: 10 Oct 2003
 TI Estrogens and non-aromatizing androgens pharmaceutical compositions for the treatment of frailty and sexual dysfunction of women undergoing estrogen replacement therapy
 IN Leonard, Thomas W.; Waldon, R. Forrest
 PA USA
 SO U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO

DT Patent
 LA English
 IC ICM A61K031-56
 NCL 514170000; 514171000
 CC 2-4 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003191096	A1	20031009	US 2002-268008	20021009
	WO 2003084546	A1	20031016	WO 2003-US2871	20030131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1494678	A1	20050112	EP 2003-746024	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-369635P	P	20020403		
	US 2002-268008	A	20021009		
	WO 2003-US2871	W	20030131		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
--	------------	-------	------------------------------------

US 2003191096	ICM	A61K031-56
	NCL	514170000; 514171000

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat frailty and sexual dysfunction in women undergoing **estrogen replacement therapy**.

ST **estrogen androgen hormone replacement therapy**
frailty sexual dysfunction

IT **Progesterogens**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (co-administered with the hormonal therapy; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **Sexual behavior**
 (disorder; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **Hormone replacement therapy**
 Human
 (estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **Androgens**
Estrogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **Bone**
 (strength increase; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction

of women undergoing estrogen replacement therapy)


IT Muscle, disease
 (weakness; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing estrogen replacement therapy)

IT 50-28-2, 17 β -Estradiol,
 biological studies 53-16-7, Estrone, biological studies 53-39-4, Oxandrolone 57-63-6, Ethinyl estradiol 57-91-0, 17 α -Estradiol 434-07-1, Oxymetholone 474-86-2, Equilin 474-87-3, Δ 8,9-Dehydroestrone 517-09-9, Equilenin 521-18-6, Stanolone 651-55-8, 17 α -Dihydroequilin 979-32-8, Estradiol valerate 1423-97-8, 17 β -Dihydroequilin 3563-27-7, 17 β -Dihydroequilin 6639-99-2, 17 α -Dihydroequilin 10418-03-8, Stanozolol 17230-88-5, Danazol 23392-54-3, 17 β Δ 8,9-Dehydroestradiol 162707-56-4, 17 α Δ 8,9-Dehydroestradiol 360792-47-8, 6-Hydroxyequilin 360796-54-9, 6-Hydroxy-17 α -dihydroequilin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing estrogen replacement therapy)

IT 50-28-2, 17 β -Estradiol,
 biological studies 53-16-7, Estrone, biological studies 53-39-4, Oxandrolone 57-91-0, 17 α -Estradiol 434-07-1, Oxymetholone 474-86-2, Equilin 474-87-3, Δ 8,9-Dehydroestrone 517-09-9, Equilenin 651-55-8, 17 α -Dihydroequilin 1423-97-8, 17 β -Dihydroequilin 3563-27-7, 17 β -Dihydroequilin 6639-99-2, 17 α -Dihydroequilin 10418-03-8, Stanozolol 17230-88-5, Danazol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing estrogen replacement therapy)

RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 474-86-2 HCPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 3 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 2002:888571 HCPLUS

DN 137:363705

ED Entered STN: 22 Nov 2002

TI Treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens

IN Leonard, Thomas W.

PA Endeavor Pharmaceuticals, USA

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61K031-57; A61P015-12

CC 2-4 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092102	A2	20021121	WO 2002-US15690	20020516
	WO 2002092102	A3	20030320		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004145	A1	20030102	US 2002-147366	20020516
	EP 1390038	A2	20040225	EP 2002-736946	20020516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004072808	A1	20040415	US 2003-678828	20031003
PRAI	US 2001-291488P	P	20010516		
	US 2002-147366	A1	20020516		
	WO 2002-US15690	W	20020516		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2002092102	ICM	A61K031-565
		ICS	A61K031-57; A61P015-12
	US 2003004145	ECLA	A61K031/566; A61K031/566+M; A61K031/569; A61K031/569+M; A61K031/57; A61K031/57+M; A61K045/06
	US 2004072808	ECLA	A61K031/566; A61K031/566+M; A61K031/569; A61K031/569+M; A61K031/57; A61K031/57+M; A61K045/06

AB A method of treating vasomotor symptoms associated with hormone deficiencies is claimed comprising: administering a dose of a therapeutic amount of an estrogenic compound to a subject; administering a dose of a therapeutic amount of a progestin agent to a subject; and administering a second dose of a therapeutic amount of a progestin agent at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of a progestin agent than said first dose. The method further comprises administering an androgen compound in a daily dose. The method can be used for treating hormonal deficiencies, including **menopause**. Also claimed is a method of preventing endometrial hyperplasia associated with estrogen therapy in a subject, said method comprising: administering continuously and uninterruptedly for a first predetd. time period a first dose of a progestin agent to said subject; and administering continuously and uninterruptedly for a second predetd. time period a second dose of a progestin agent to said subject.

ST hormone deficiency condition treatment progestin estrogen androgen

IT Estrogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(conjugated, estrogen; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT Hyperplasia

(endometrial; method of preventing endometrial hyperplasia associated with

estrogen therapy by administration of progestins)

IT Uterus, disease
 (endometrium, hyperplasia; method of preventing endometrial hyperplasia associated with estrogen therapy by administration of progestins)

IT Androgens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of conditions relating to hormone deficiencies by administration of estrogens, progestins, and androgens)

IT **Hormone replacement therapy**
 Human
 (treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT Estrogens
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT Hormones, animal, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT Progestogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT **Menopause**
 (treatment; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT Blood vessel, disease
 (vasomotor symptoms; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

IT **53-39-4, Oxandrolone 53-39-4D,**
Oxandrolone, esters and salts 53-41-8, Androsterone 53-41-8D,
Androsterone, esters and salts 53-43-0, Dehydroepiandrosterone
53-43-0D, Dehydroepiandrosterone, esters and salts 58-18-4, Methyl
testosterone 58-18-4D, Methyl testosterone, esters and salts 58-22-0,
Testosterone 58-22-0D, Testosterone, esters and salts 76-43-7,
Fluoxymesterone 76-43-7D, Fluoxymesterone, esters and salts
434-07-1, Oxymetholone 434-07-1D,
Oxymetholone, esters and salts 514-61-4 514-61-4D, esters and
salts 846-46-8 846-46-8D, esters and salts 1474-55-1, Nandrolone
benzoate 1474-55-1D, Nandrolone benzoate, esters and salts 1852-53-5
1852-53-5D, esters and salts 10418-03-8, Stanozolol
10418-03-8D, Stanozolol, esters and salts
17230-88-5, Danazol 17230-88-5D,
Danazol, esters and salts
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (androgen; treatment of conditions relating to hormone deficiencies by administration of estrogens, progestins, and androgens)

IT **50-28-2, 17 β -Estradiol,**
 biological studies **50-28-2D, 17 β -**
Estradiol, mixts., conjugates, and salts 53-16-7,
Estrone, biological studies 53-16-7D, Estrone,
mixts., conjugates, and salts 57-63-6, Ethinyl estradiol
57-63-6D, Ethinyl estradiol, mixts., conjugates, and salts
57-91-0, 17 α -Estradiol
57-91-0D, 17 α -Estradiol,
mixts., conjugates, and salts 474-86-2, Equilin
474-86-2D, Equilin, mixts., conjugates, and salts
474-87-3, Δ 8,9-Dehydroestrone 474-87-3D,

$\Delta 8,9$ -Dehydroestrone, mixts., conjugates, and salts 517-09-9
, Equilenin 517-09-9D, Equilenin, mixts., conjugates, and salts
651-55-8, 17 α -Dihydroequilin
651-55-8D, 17 α -Dihydroequilin,
mixts., conjugates, and salts 979-32-8, Estradiol valerate
979-32-8D, Estradiol valerate, mixts., conjugates, and salts
1423-97-8, 17 β -Dihydroequilenin
1423-97-8D, 17 β -Dihydroequilenin
, mixts., conjugates, and salts 3563-27-7, 17
 β -Dihydroequilin 3563-27-7D, 17
 β -Dihydroequilin, mixts., conjugates, and salts
6639-99-2, 17 α -Dihydroequilenin
6639-99-2D, 17 α -Dihydroequilenin
, mixts., conjugates, and salts 23392-54-3, 17 β - $\Delta 8,9$ -
Dehydroestradiol 23392-54-3D, 17 β - $\Delta 8,9$ -Dehydroestradiol,
mixts., conjugates, and salts 162707-56-4, 17 α - $\Delta 8,9$ -
Dehydroestradiol 162707-56-4D, 17 α - $\Delta 8,9$ -Dehydroestradiol,
mixts., conjugates, and salts 360792-45-6, 6-Hydroxy-17
 β -dihydroequilenin 360792-45-6D, 6-Hydroxy-
17 β -dihydroequilenin, mixts., conjugates,
and salts 360792-47-8, 6-Hydroxyequilenin 360792-47-8D,
6-Hydroxyequilenin, mixts., conjugates, and salts 360796-54-9,
6-Hydroxy-17 α -dihydroequilenin
360796-54-9D, 6-Hydroxy-17 α -
dihydroequilenin, mixts., conjugates, and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(estrogen; treatment of conditions relating to hormone deficiencies by
administration of progestins, estrogens, and androgens)

IT 51-98-9, Norethindrone acetate 52-76-6, Lynestrenol 57-83-0,
Progesterone, biological studies 68-22-4, Norethindrone 68-23-5,
Norethynodrel 71-58-9, Medroxyprogesterone acetate 79-64-1,
Dimethisterone 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate
302-22-7, Chlormadinone acetate 427-51-0, Cyproterone acetate
432-60-0, Allylestrenol 434-03-7, Ethisterone 434-22-0,
19-Nortestosterone 516-55-2, 5 α -Pregn-3 β -ol-20-one
566-61-0 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone
caproate 797-63-7, Levonorgestrel 848-21-5, Norgestriene 977-79-7,
Medrogestone 3000-39-3, Quingestanol acetate 6533-00-2, dl-Norgestrel
35189-28-7, Norgestimate 54024-22-5, Desogestrel 60282-87-3, Gestodene
74513-62-5, Trimegestone 213474-56-7 475472-71-0, 5 α -Pregnan-
3 β ,20 β -diol sulfate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(progestin; treatment of conditions relating to hormone deficiencies by
administration of progestins, estrogens, and androgens)

IT 53-39-4, Oxandrolone 53-39-4D,
Oxandrolone, esters and salts 434-07-1,
Oxymetholone 434-07-1D, Oxymetholone, esters
and salts 10418-03-8, Stanozolol 10418-03-8D
, Stanozolol, esters and salts 17230-88-5,
Danazol 17230-88-5D, Danazol, esters and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(androgen; treatment of conditions relating to hormone deficiencies by
administration of estrogens, progestins, and androgens)

RN 53-39-4 HCAPLUS


CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 10418-03-8 HCAPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCAPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, 17 β -Estradiol,

biological studies 50-28-2D, 17 β -

Estradiol, mixts., conjugates, and salts 53-16-7,

Estrone, biological studies 53-16-7D, Estrone,

mixts., conjugates, and salts 57-91-0, 17

α -Estradiol 57-91-0D, 17

α -Estradiol, mixts., conjugates, and salts

474-86-2, Equilin 474-86-2D, Equilin

, mixts., conjugates, and salts 474-87-3, Δ 8,9-

Dehydroestrone 474-87-3D, Δ 8,9-Dehydroestrone, mixts.,

conjugates, and salts 517-09-9, Equilenin 517-09-9D,

Equilenin, mixts., conjugates, and salts 651-55-8, 17

α -Dihydroequilin 651-55-8D, 17

α -Dihydroequilin, mixts., conjugates, and salts

1423-97-8, 17 β -Dihydroequilenin

1423-97-8D, 17 β -Dihydroequilenin

, mixts., conjugates, and salts 3563-27-7, 17

β -Dihydroequilin 3563-27-7D, 17

β -Dihydroequilin, mixts., conjugates, and salts

6639-99-2, 17 α -Dihydroequilenin

6639-99-2D, 17 α -Dihydroequilenin

, mixts., conjugates, and salts


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(estrogen; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 57-91-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-86-2 HCAPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-86-2 HCAPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCAPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCAPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCAPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCAPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCAPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCAPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:574935 HCAPLUS

DN 137:120059

ED Entered STN: 02 Aug 2002

TI Method of treating hormonal deficiencies in women undergoing
estrogen replacement therapy

IN Leonard, Thomas W.; Waldon, R. Forrest

PA Endeavor Pharmaceuticals, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61P005-24

CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058706	A2	20020801	WO 2001-US51045	20011221 <--
	WO 2002058706	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151530	A1	20021017	US 2001-29424	20011220 <--
	CA 2431645	AA	20020801	CA 2001-2431645	20011221 <--
	EP 1343509	A2	20030917	EP 2001-989306	20011221 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520375	T2	20040708	JP 2002-559040	20011221 <--
	US 2003195177	A1	20031016	US 2003-424243	20030429 <--
PRAI	US 2000-258142P	P	20001222	<--	
	US 2001-29424	A3	20011220	<--	
	WO 2001-US51045	W	20011221	<--	

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2002058706	ICM	A61K031-565
	ICS	A61P003-24
JP 2004520375	FTERM	4C086/AA01; 4C086/AA02; 4C086/DA09; 4C086/DA10; 4C086/DA12; 4C086/DA13; 4C086/MA02; 4C086/MA04; 4C086/MA52; 4C086/NA06; 4C086/NA14; 4C086/ZA16; 4C086/ZA36; 4C086/ZA81; 4C086/ZA97; 4C086/ZC11; 4C086/ZC75

<--

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing **estrogen replacement therapy**. The combined estrogen and non-aromatizing androgen therapy has less of a detrimental effect on the **uterus** than traditional **estrogen replacement therapy**. A progestin may also be administered along with the estrogen and the androgen. Pharmaceutical **compns.** are claimed along with the method of treatment.

ST nonaromatizing androgen **estrogen replacement therapy** women

IT Progestogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**hormone replacement therapy** in women

with an estrogen, a nonaromatizing androgen, and a progestin)

IT **Uterus**

(**hormone replacement therapy** with estrogen and nonaromatizing androgen with a reduced neg. effect on the uterus)

IT Drug delivery systems

(method of treating hormonal deficiencies in women by using a drug formulation containing an estrogen and a non-aromatizing androgen)

IT **Hormone replacement therapy**

Human

(method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy** by

administering non-aromatizing androgens)

IT Androgens

Estrogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating hormonal deficiencies in women undergoing estrogen replacement therapy by administering non-aromatizing androgens)

IT 50-28-2, 17 β -Estradiol,

biological studies 50-28-2D, 17 β -

Estradiol, mixts., conjugates, and salts 53-16-7,

Estrone, biological studies 53-16-7D, Estrone,

mixts., conjugates, and salts 53-39-4, Oxandrolone

53-39-4D, Oxandrolone, esters and salts 57-63-6,

Ethinyl estradiol 57-63-6D, Ethinyl estradiol,

mixts., conjugates, and salts 57-91-0, 17

α -Estradiol 57-91-0D, 17

α -Estradiol, mixts., conjugates, and salts

434-07-1, Oxymetholone 434-07-1D,

Oxymetholone, esters and salts 474-86-2, Equilin

474-86-2D, Equilin, mixts., conjugates, and salts

474-87-3, Δ 8,9-Dehydroestrone 474-87-3D,

Δ 8,9-Dehydroestrone, mixts., conjugates, and salts 517-09-9

, Equilenin 517-09-9D, Equilenin, mixts., conjugates, and salts

651-55-8, 17 α -Dihydroequilin

651-55-8D, 17 α -Dihydroequilin,

mixts., conjugates, and salts 979-32-8, Estradiol valerate

979-32-8D, Estradiol valerate, mixts., conjugates, and salts

1423-97-8, 17 β -Dihydroequilin

1423-97-8D, 17 β -Dihydroequilin

, mixts., conjugates, and salts 3563-27-7, 17

β -Dihydroequilin 3563-27-7D, 17

β -Dihydroequilin, mixts., conjugates, and salts

6639-99-2, 17 α -Dihydroequilin

6639-99-2D, 17 α -Dihydroequilin

, mixts., conjugates, and salts 10418-03-8, Stanozolol

10418-03-8D, Stanozolol, esters and salts

17230-88-5, Danazol 17230-88-5D,

Danazol, esters and salts 23392-54-3, 17 β - Δ 8,9-

Dehydroestradiol 23392-54-3D, 17 β - Δ 8,9-Dehydroestradiol,

mixts., conjugates, and salts 162707-56-4, 17 α - Δ 8,9-

Dehydroestradiol 162707-56-4D, 17 α - Δ 8,9-Dehydroestradiol,

mixts., conjugates, and salts 360792-45-6, 6-Hydroxy-17

β -Dihydroequilin 360792-45-6D, mixts.,

conjugates, and salts 360792-47-8, 6-Hydroxyequilin 360792-47-8D,

6-Hydroxyequilin, mixts., conjugates, and salts 360796-54-9,

6-Hydroxy-17 α -dihydroequilin

360796-54-9D, mixts., conjugates, and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(method of treating hormonal deficiencies in women undergoing

estrogen replacement therapy by

administering non-aromatizing androgens)

IT 50-28-2, 17 β -Estradiol,

biological studies 50-28-2D, 17 β -

Estradiol, mixts., conjugates, and salts 53-16-7,

Estrone, biological studies 53-16-7D, Estrone,

mixts., conjugates, and salts 53-39-4, Oxandrolone

53-39-4D, Oxandrolone, esters and salts 57-91-0

, 17 α -Estradiol 57-91-0D,

17 α -Estradiol, mixts., conjugates, and

salts 434-07-1, Oxymetholone 434-07-1D,


Oxymetholone, esters and salts 474-86-2, Equilin

474-86-2D, Equilin, mixts., conjugates, and salts
474-87-3, Δ 8,9-Dehydroestrone 474-87-3D,
 Δ 8,9-Dehydroestrone, mixts., conjugates, and salts 517-09-9
, Equilenin 517-09-9D, Equilenin, mixts., conjugates, and salts
651-55-8, 17 α -Dihydroequilin
651-55-8D, 17 α -Dihydroequilin,
mixts., conjugates, and salts 1423-97-8, 17
 β -Dihydroequilenin 1423-97-8D, 17
 β -Dihydroequilenin, mixts., conjugates, and salts
3563-27-7, 17 β -Dihydroequilin
3563-27-7D, 17 β -Dihydroequilin,
mixts., conjugates, and salts 6639-99-2, 17
 α -Dihydroequilenin 6639-99-2D,
17 α -Dihydroequilenin, mixts.,
conjugates, and salts 10418-03-8, Stanozolol
10418-03-8D, Stanozolol, esters and salts
17230-88-5, Danazol 17230-88-5D,
Danazol, esters and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method of treating hormonal deficiencies in women undergoing
estrogen replacement therapy by
administering non aromatizing androgens)

administering
RN 50-38-3 HCABLIUS

30-28-2 HCAELOS
CN Estra-1,3,5(10)-triene-3,17-diol (178)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-39-4 HCAPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 434-07-1 HCAPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 474-86-2 HCAPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-86-2 HCAPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCAPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCAPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCAPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:504629 HCAPLUS
DN 137:83634
ED Entered STN: 05 Jul 2002
TI Estrogen, androgen and vasodilator compositions for the treatment of female sexual dysfunction
IN Leonard, Thomas W.; Waldon, R. Waldon
PA Endeavor Pharmaceuticals, USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-565
 ICS A61P015-12
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2

FAN.CNT 1		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051420	A2	20020704	WO 2001-US49978	20011221 <--
	WO 2002051420	A3	20021227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HŘ, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	2002107230	A1	20020808	US 2001-29423	20011220 <--
CA	2431834	AA	20020704	CA 2001-2431834	20011221 <--
EP	1359920	A2	20031112	EP 2001-992297	20011221 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004520320	T2	20040708	JP 2002-552564	20011221 <--
US	2004259817	A1	20041223	US 2004-898104	20040723 <--
PRAI	US 2000-257745P	P	20001222	<--	
	US 2001-29423	A1	20011220		
	WO 2001-US49978	W	20011221		

CLASS	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002051420		ICM	A61K031-565
		ICS	A61P015-12
US 2002107230		ECLA	A61K031/56+M; A61K031/565; A61K031/565+M; A61K031/57+M; A61K045/06
JP 2004520320		FTERM	4C084/AA02; 4C084/AA03; 4C084/AA22; 4C084/AA27;

4C084/NA05; 4C084/NA14; 4C084/ZA811; 4C086/AA01;
 4C086/BC27; 4C086/BC38; 4C086/DA08; 4C086/DA09;
 4C086/DA10; 4C086/DA12; 4C086/DA13; 4C086/MA03;
 4C086/MA04; 4C086/MA28; 4C086/MA31; 4C086/MA32;
 4C086/MA35; 4C086/MA52; 4C086/MA56; 4C086/MA63;
 4C086/NA05; 4C086/NA14; 4C086/ZA81 <--
 US 2004259817 ECLA A61K031/56+M; A61K031/565; A61K031/565+M; A61K031/57+M;
 A61K045/06 <--

AB A pharmaceutical composition for the treatment of sexual dysfunction, particularly post-menopausal females, is provided. The composition includes a therapeutically effective amount of an estrogenic compound, androgenic compound, vasodilation compound, and a pharmaceutically acceptable carrier. Tablets were prepared containing and estrogen such as estradiol, an androgen such as methyltestosterone and a vasodilator such as phentolamine and excipients.

ST estrogen androgen vasodilator compn female sexual dysfunction

IT Sexual behavior

(disorder, female; estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Vasodilators

(estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Androgens

Estrogens

Progesterogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Drug delivery systems

(tablets; estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Drug delivery systems

(topical; estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Drug delivery systems

(vaginal; estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT Adrenoceptor antagonists

(α -; estrogen, androgen and vasodilator compns. for the treatment of female sexual dysfunction)

IT 50-28-2, 17 β -Estradiol,

biological studies 51-98-9, Norethindrone acetate 52-76-6, Lynestrenol

53-16-7, Estrone, biological studies 53-39-4,

Oxandrolone 53-41-8, Androsterone 53-43-0,

Dehydroepiandrosterone 57-63-6, Ethinylestradiol 57-91-0,

17 α -Estradiol 58-00-4, Apomorphine

58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-22-0,

Testosterone 62-90-8, Nandrolone phenylpropionate 63-05-8,

Androstenedione 65-28-1, Phentolamine mesylate 68-22-4, Norethindrone

68-23-5, Norethynodrel 71-58-9, Medroxyprogesterone acetate 73-05-2,

Phentolamine hydrochloride 76-43-7, Fluoxymesterone 79-64-1,

Dimethisterone 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate

302-22-7, Chlormadinone acetate 302-23-8, Hydroxyprogesterone acetate

360-70-3, Nandrolone decanoate 427-51-0, Cyproterone acetate 432-60-0,

Allylestrenol 434-03-7, Ethisterone 434-07-1,

Oxymetholone 434-22-0, 19-Nortestosterone 474-86-2,

Equilin 474-87-3, Δ 8,9-Dehydroestrone 514-61-4,

17 α -Methyl-19-nortestosterone 516-55-2, 5 α -Pregnan-3 β -

ol-20-one 517-09-9, Equilenin 520-85-4, Medroxyprogesterone

521-12-0, Dromostanolone propionate 521-17-5, Androstenediol 521-18-6,

4-Dihydrotestosterone 566-61-0 566-65-4 595-33-5, Megestrol acetate

630-56-8, Hydroxyprogesterone caproate 651-55-8, 17


α -Dihydroequilin 797-63-7, Levonorgestrel

848-21-5, Norgestriencone 912-57-2, Nandrolone cyclohexanepropionate
 965-90-2, Ethylestrenol 968-93-4, Testolactone 977-79-7, Medrogestone
 979-32-8, Estradiol valerate 1099-87-2, Sodium
 dehydroepiandrosterone sulfate 1164-95-0, Androsterone acetate
 1323-54-2, Acetoxypregnolone 1423-97-8, 17
 β -Dihydroequilenin 1474-55-1, Nandrolone benzoate
 2098-66-0, Cyproterone 2529-45-5, Flurogestone acetate 2919-66-6,
 Melengestrol acetate 3000-39-3, Quingestanol acetate 3137-73-3,
 Anagestone acetate 3562-63-8, Megestrol 3563-27-7, 17
 β -Dihydroequilin 5721-91-5, Testosterone
 decanoate 5953-68-4, Androsterone propionate 5953-69-5, Androsterone
 benzoate 6533-00-2, Norgestrel 6639-99-2, 17
 α -Dihydroequilenin 7642-64-0, Nandrolone
 furylpropionate 10418-03-8, Stanozolol 14291-86-2
 18470-94-5, Nandrolone cyclohexanecarboxylate 23392-54-3,
 17 β - Δ 8,9-Dehydroestradiol 32717-60-5 35189-28-7,
 Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel
 58652-20-3, Nomegestrol acetate 60282-87-3, Gestodene 74513-62-5,
 Trimegestone 103062-96-0 162707-56-4, 17 α - Δ 8,9-
 Dehydroestradiol 213474-56-7 360792-45-6 360792-47-8,
 6-Hydroxyequilenin 360796-54-9 439928-64-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogen, androgen and vasodilator compns. for the treatment
 of female sexual dysfunction)

IT 50-28-2, 17 β -Estradiol,
 biological studies 53-16-7, Estrone, biological
 studies 53-39-4, Oxandrolone 57-91-0,
 17 α -Estradiol 434-07-1,
 Oxymetholone 474-86-2, Equilin
 474-87-3, Δ 8,9-Dehydroestrone 517-09-9, Equilenin
 651-55-8, 17 α -Dihydroequilin
 1423-97-8, 17 β -Dihydroequilenin
 3563-27-7, 17 β -Dihydroequilin
 6639-99-2, 17 α -Dihydroequilenin
 10418-03-8, Stanozolol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogen, androgen and vasodilator compns. for the treatment
 of female sexual dysfunction)


RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 474-86-2 HCPLUS

CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474-87-3 HCPLUS

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651-55-8 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1423-97-8 HCAPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3563-27-7 HCAPLUS

CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6639-99-2 HCPLUS

CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 6 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 2002:353298 HCPLUS

DN 136:350812

ED Entered STN: 12 May 2002

TI GnRH analogues for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs

IN Arnold, Susi; Reichler, Iris; Hubler, Madeleine

PA University of Zurich, Switz.

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K038-09

ICS A61K045-06; A61P015-12; A61P013-00

CC 2-5 (Mammalian Hormones)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036144	A1	20020510	WO 2001-CH636	20011026 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PH, PL,				

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2427731 AA 20020510 CA 2001-2427731 20011026 <--
 AU 2001095359 A5 20020515 AU 2001-95359 20011026 <--
 EP 1330257 A1 20030730 EP 2001-975948 20011026 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001015067 A 20040406 BR 2001-15067 20011026 <--
 JP 2004512369 T2 20040422 JP 2002-538955 20011026 <--
 US 2004023878 A1 20040205 US 2003-415519 20030430
 PRAI EP 2000-811011 A 20001030 <--
 WO 2001-CH636 W 20011026

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002036144	ICM	A61K038-09
	ICS	A61K045-06; A61P015-12; A61P013-00
JP 2004512369	FTERM	4C076/AA01; 4C076/AA03; 4C076/AA93; 4C076/BB01; 4C076/BB25; 4C076/BB29; 4C076/BB30; 4C076/BB31; 4C076/CC17; 4C084/AA02; 4C084/AA17; 4C084/BA01; 4C084/BA09; 4C084/BA17; 4C084/BA23; 4C084/CA59; 4C084/MA12; 4C084/MA31; 4C084/MA52; 4C084/MA55; 4C084/MA56; 4C084/MA59; 4C084/MA60; 4C084/MA63; 4C084/NA14; 4C084/ZA811
US 2004023878	ECLA	A61K038/09; A61K045/06

AB The use of at least one GnRH analog for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed. The GnRH analog is selected from the group consisting of deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprorelin acetate, danazol, Cetrorelix or mixts. thereof. The medicament can further comprise another active substance selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent, or mixts. thereof. The addnl. active ingredient can also be an α -adrenergic agonist, a β -adrenergic receptor blocking agent, a cholinergic receptor blocking compound, a cholinergic receptor stimulating drug, a smooth muscle relaxant, a nitric oxide synthase substrate, a nitric oxide donor, or mixts. thereof.

ST GnRH analog treatment ovariectomy menopause symptom treatment

IT Canis familiaris

Human

Ovariectomy

(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Cholinergic agonists

Cholinergic antagonists

(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Estrogens

Progesterogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Behavior

(aggressive; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Fur
Hair
Skin
(changes; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Mental disorder
(depression; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Menopause
(disorder, hot flash; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Menopause
(disorder, vasomotor symptoms; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Bladder, disease
(incontinence; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(intravaginal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Emotion
(mood changes; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(nasal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(oral; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(parenterals; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Menopause
(postmenopause; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Menopause
(premenopause; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(rectal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(s.c. implant; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(s.c.; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(slow-release; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Muscle relaxants
(smooth; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(transdermal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Adrenoceptor agonists
(α -; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Adrenoceptor antagonists
(β -; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT 9034-40-6D, GnRH, analogs 17230-88-5, Danazol 34973-08-5, Gonadorelin acetate 68630-75-1, Buserelin acetate 74381-53-6, Leuprolide acetate 76932-60-0, Nafarelin acetate 82318-06-7, Deslorelin acetate 120287-85-6, Cetrorelix 145781-92-6, Goserelin acetate 160296-12-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT 50-27-1, Estriol 50-28-2, 17 β -
Estradiol, biological studies 53-16-7, **Estrone**, biological studies 57-83-0, **Progesterone**, biological studies 68-22-4, **Norethisterone** 68-96-2, **Hydroxyprogesterone** 520-85-4, **Medroxyprogesterone** 797-63-7, **Levonorgestrel** 979-32-8, **Estradiol valerate** 6533-00-2, **Norgestrel** 10540-29-1, **Tamoxifen** 31477-60-8, **Centchroman** 60282-87-3, **Gestodene** 67392-87-4, **Drospirenone** 84449-90-1, **Raloxifene** 89778-26-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(donors; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT 125978-95-2, Nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(substrates; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Conn, P; NEW ENGLAND JOURNAL OF MEDICINE 1991, V324, P93 HCAPLUS
(2) Janssens, L; VETERINARY RECORD 1997, V141(24), P620 MEDLINE
(3) Praecis Pharm Inc; WO 9955358 A 1999 HCAPLUS

IT 17230-88-5, Danazolum


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, 17 β -Estradiol,

biological studies 53-16-7, Estrone, biological studies


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L60 ANSWER 7 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN
AN 2000:900464 HCPLUS
DN 134:37563
ED Entered STN: 22 Dec 2000
TI Administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or those receiving estrogen supplementation
IN Rosario-jansen, Theresa; Mazer, Norman A.
PA Watson Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-56
CC 2-4 (Mammalian Hormones)
EAN CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076522	A1	20001221	WO 2000-US15834	20000609 <-
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2376797	AA	20001221	CA 2000-2376797	20000609 <-
EP	1189619	A1	20020327	EP 2000-939710	20000609 <-
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR	2000011740	A	20020514	BR 2000-11740	20000609 <-
TR	200200406	T2	20020621	TR 2002-200200406	20000609 <-
JP	2003505345	T2	20030212	JP 2001-502855	20000609 <-
US	6583129	B1	20030624	US 2000-591141	20000609 <-
NZ	516502	A	20040326	NZ 2000-516502	20000609 <-
AU	775145	B2	20040722	AU 2000-54758	20000609 <-
RU	2234920	C2	20040827	RU 2002-100356	20000609 <-
NO	2001006046	A	20020206	NO 2001-6046	20011211 <-
ZA	2001010181	A	20021211	ZA 2001-10181	20011211 <-
US	2003153540	A1	20030814	US 2002-278033	20021022 <-
PRAI	US 1999-138851P	P	19990611	<-	
	US 1999-138854P	P	19990611	<-	
	US 1999-139323P	P	19990611	<-	
	US 2000-591141	A1	20000609	<-	
	WO 2000-US15834	W	20000609	<-	

WO 2000076522 ICM A61K031-56

AB The present invention provides compns., methods, and kits for improving health in a woman having elevated sex hormone binding globulin (SHBG) levels, or who is receiving oral estrogen supplementation, by non-orally administering an effective amount of an androgenic steroid. Further, the present invention provides compns., methods and kits for coadministering an effective amount of an orally administered estrogen and an effective amount of a non-orally administered androgenic steroid for women in need of estrogen supplementation. For example, a transdermal testosterone patch (300 mcg/day nominal delivery) can be used in patients concomitantly receiving transdermal estradiol or oral conjugated equine estrogens. Progestin may also be administered along with estrogen and androgen in order to provide endometrial safety or effective contraception. Improvement in the health of the woman, is manifested by restoration, enhancement, or improvement of sexual activity, vital energy, sense of wellbeing, mood and sense of emotional well being, shyness, cognitive abilities, muscle mass and function, body compn ., bone mineral d., skin and hair condition, pubic hair, urogenital atrophy, vaginal dryness, dry eyes, health in autoimmune conditions, vasomotor instability, breast tenderness, and symptoms of premenstrual syndrome.

ST androgen estrogen administration women improved health

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SERMs (selective estrogen receptor modulators); administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Globulins, biological studies

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (SHBG (sex hormone-binding globulin); administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Hormone replacement therapy

Menopause

(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Androgens

Estrogens

Progesterogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Urogenital tract

(atrophy, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Mineral elements, biological studies

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

BIOL (Biological study); OCCU (Occurrence)

(bone, d., improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Hair

Skin

(condition, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(conjugated; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Eye, disease

(dry, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Vagina

(dryness, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Autoimmune disease

(health in, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxy, esters; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Energy metabolism, animal

(improved energy; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Cognition**Sexual behavior**

(improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Muscle

(mass, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Bone

(minerals, d., improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phytoestrogens; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Menopause

(postmenopause; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Ovarian cycle

(premenstrual syndrome, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Mammary gland

(tenderness, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Circulation

(vasomotor instability, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Emotion
 (well being; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT 57-83-0, Progestin, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen and progestin supplementation)

IT 50-28-2, 17 β -Estradiol,
 biological studies 52-78-8, Norethandrolone 53-16-7,
 Estrone, biological studies 53-39-4, Oxandrolone
 53-41-8, Androsterone 53-43-0, Dehydroepiandrosterone 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 57-91-0,
 17 α -Estradiol 58-18-4,
 Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0,
 Testosterone 63-05-8, Androstenedione 71-58-9, Medroxyprogesterone acetate 72-63-9, Methandrostenolone 76-43-7, Fluoxymesterone 145-13-1, Pregnenolone 315-37-7, Testosterone enanthate 382-45-6, Adrenosterone 434-07-1, Oxymetholone 434-22-0,
 Nandrolone 438-67-5, Sodium estrone sulfate 514-61-4
 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4,
 Testolactone 1045-69-8, Testosterone acetate 1424-00-6, Mesterolone 1605-89-6, Bolasterone 5704-03-0, Testosterone phenylacetate 5721-91-5, Testosterone decanoate 10418-03-8, Stanozolol 15262-86-9, Testosterone isocaproate 17230-88-5, Danazol 105165-22-8, Testosterone buciclate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Chein, E; US 5855920 A 1999 HCPLUS
- (2) Hughes; US 5962021 A 1999 HCPLUS
- (3) Labrie, F; US 5550107 A 1996 HCPLUS

IT 50-28-2, 17 β -Estradiol,
 biological studies 53-16-7, Estrone, biological studies 53-39-4, Oxandrolone 57-91-0,
 17 α -Estradiol 434-07-1,
 Oxymetholone 10418-03-8, Stanozolol 17230-88-5, Danazol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

RN 50-28-2 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-91-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCAPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 10418-03-8 HCAPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 8 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 2000:475529 HCPLUS

DN 133:94499

ED Entered STN: 14 Jul 2000

TI Hormone replacement for breast cancer patients

IN Holmes' replacement is

IN Hughes, Claude B., Jr.
PA Cedars-Sinai Medical Center. USA

SO PCT Int. Appl., 21 pp.

50 for the App
CODEN: PTXXD2

DT Patent

DI raccolte
LA English

EA ENGLISH
TC TCM A61K031-00

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 2

FAN CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040230	A2	20000713	WO 2000-US96	20000104 <--
	WO 2000040230	A3	20010517		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-226068 A 19990106 <--

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2000040330 TCM : A61K031-00

AB Disclosed is a method of androgen replacement therapy to maintain or restore a woman's physiol. normality, including her bone d., vasomoter stability, sexual function, and energy. Also described is a method of treating or preventing osteoporosis in women. A woman is administered pharmaceutical compns., comprising a non-aromatizable androgen, without estradiol or any estrogenic compound, by a route other than the digestive tract, such that 5 to 500 µg of the non-aromatizable androgen is administered daily. Pharmaceutical compns. for delivering a non-aromatizable androgen to a woman at higher than normal risk of breast cancer or endometrial cancer, are formulated to deliver an ED transdermally, transmucosally or by any delivery route, except the digestive tract. Non-aromatizable androgens that are contemplated include, but are not limited to, methyltestosterone, 17-alpha-methyl-19-nor-testosterone, danazol, fluoxymesterone, methandrostenolone, oxandrolone, oxymetholone, stanozolol, and testolactone. But also contemplated among useful non-aromatizable

androgens are androgenic progestins, including desogestrel, norgestimate, norethindrone, norethindrone acetate, norgestrel, ethynodiol diacetate and levonorgestrel. The absence from these compns. of estradiol, or any estrogenic compound, such as testosterone, avoids the estrogen exposure which increases the cancer risk. Androgen delivery other than by ingestion permits lower EDs and thus lowers the risk of virilizing effects and potential liver toxicity than previously available androgen replacement preps.

ST androgen replacement therapy breast cancer

IT Drug delivery systems
(adhesive patches; non-aromatizable androgen replacement for breast cancer patients)

IT Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (androgenic; non-aromatizable androgen replacement for breast cancer patients)

IT Uterus, neoplasm
Uterus, neoplasm
(endometrium, inhibitors; non-aromatizable androgen replacement for breast cancer patients)

IT Antitumor agents
Uterus, neoplasm
(endometrium; non-aromatizable androgen replacement for breast cancer patients)

IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(exclusion of; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(gels; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(implants; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(injections; non-aromatizable androgen replacement for breast cancer patients)

IT Antitumor agents
(mammary gland; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(mucosal; non-aromatizable androgen replacement for breast cancer patients)

IT Mammary gland
Mammary gland
(neoplasm, inhibitors; non-aromatizable androgen replacement for breast cancer patients)

IT Mammary gland
(neoplasm; non-aromatizable androgen replacement for breast cancer patients)

IT Osteoporosis
(non-aromatizable androgen replacement for breast cancer patients)

IT Androgens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(ointments, creams; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems

(oral; non-aromatizable androgen replacement for breast cancer patients)

IT Osteoporosis
 (therapeutic agents; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems.
 (transdermal; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
 (vaginal; non-aromatizable androgen replacement for breast cancer patients)


IT 50-28-2, Estradiol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (exclusion of; non-aromatizable androgen replacement for breast cancer patients)

IT 51-98-9, Norethindrone acetate 53-39-4, Oxandrolone
 58-18-4, Methyltestosterone 68-22-4, Norethindrone 72-63-9,
 Methandrostenolone 76-43-7, Fluoxymesterone 297-76-7, Ethynodiol
 diacetate 434-07-1, Oxymetholone 514-61-4,
 17 α -Methyl-19-nor-testosterone 521-18-6, 5 α -
 Dihydrotestosterone 797-63-7, Levonorgestrel 968-93-4, Testolactone
 6533-00-2, Norgestrel 10418-03-8, Stanozolol
 17230-88-5, Danazol 35189-28-7, Norgestimate
 54024-22-5, Desogestrel
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (non-aromatizable androgen replacement for breast cancer patients)

IT 50-28-2, Estradiol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (exclusion of; non-aromatizable androgen replacement for breast cancer patients)

RN 50-28-2 HCPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 53-39-4, Oxandrolone 434-07-1,
 Oxymetholone 10418-03-8, Stanozolol
 17230-88-5, Danazol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (non-aromatizable androgen replacement for breast cancer patients)

RN 53-39-4 HCPLUS
 CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
 4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCAPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 10418-03-8 HCAPLUS

CN 2'-H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:116900 HCAPLUS
 DN 132:156868
 ED Entered STN: 18 Feb 2000
 TI Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption
 IN Hargreaves, Richard John; Rupniak, Nadia Melanie
 PA Merck Sharp & Dohme Limited, UK
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-5377
 ICS A61K031-675; A61K031-5375; A61K031-438; A61K031-4545; A61K031-454;
 A61K031-451; A61K031-4035; A61K031-404; A61K031-4709; A61K031-00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007598	A1	20000217	WO 1999-GB2509	19990730 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2339146	AA	20000217	CA 1999-2339146	19990730 <--
	AU 9950599	A1	20000228	AU 1999-50599	19990730 <--
	AU 763615	B2	20030731		
	EP 1102590	A1	20010530	EP 1999-934993	19990730 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002522389	T2	20020723	JP 2000-563283	19990730 <--
PRAI	GB 1998-16897	A	19980804	<--	
	WO 1999-GB2509	W	19990730	<--	

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000007598	ICM	A61K031-5377	
	ICS	A61K031-675; A61K031-5375; A61K031-438; A61K031-4545; A61K031-454; A61K031-451; A61K031-4035; A61K031-404; A61K031-4709; A61K031-00	
WO 2000007598	ECLA	A61K031/00+A; A61K031/4035; A61K031/404; A61K031/438; A61K031/451; A61K031/454; A61K031/4545; A61K003/4709; A61K031/5375; A61K031/5377; A61K031/675	<--

OS MARPAT 132:156868

AB The present invention relates to the use of NK-1 receptor antagonist compns. for the treatment or prevention of abnormal bone resorption, optionally in combination with 1 or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones. Thus, tablets contained NK-1 receptor antagonist 50.0, microcryst. cellulose 80.0, modified food corn starch 80.0, lactose 189.5, and Mg stearate 0.5 mg/tablet.

ST NK1 receptor antagonist abnormal bone resorption; estrogen receptor bone resorption pharmaceutical; bisphosphonate bone resorption pharmaceutical

IT Osteoporosis
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Estrogens
Progesterones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Tachykinin receptors
(NK1 antagonists; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone, disease
(Paget's; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone
(demineralization; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Periodontium
(disease; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormones; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Androgen receptors
Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone, disease
(osteolysis, periprosthetic; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Osteoporosis
(postmenopausal; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone
(resorption; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Drug delivery systems
(tablets; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Osteoporosis
(therapeutic agents; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT 50-28-2, Estradiol, biological studies 52-78-8,
Norethandrolone 53-39-4, Oxandrolone 53-43-0,
Dehydroepiandrosterone 57-85-2, Testosterone propionate 58-18-4,
Methyltestosterone 58-22-0, Testosterone 63-05-8, Androstenedione

68-22-4, Norethisterone 72-63-9, Methandrostenolone 76-43-7,
 Fluoxymesterone 315-37-7, Testosterone enanthate 360-70-3, Nandrolone
 decanoate 434-07-1, **Oxymetholone** 434-22-0,
 19-Nortestosterone 521-17-5, Androstenediol 521-18-6,
 5 α -Dihydrotestosterone 968-49-0 977-35-5, Epiandrosterone
 sulfate 1845-11-0, Nafoxidine 2809-21-4 5591-27-5, Clometherone
 9007-12-9, Calcitonin 10418-03-8, **Stanozolol**
 10448-84-7, Nitromifene 10540-29-1, Tamoxifen 10596-23-3 15262-77-8,
 Delmadinone 17230-88-5, **Danazol** 31477-60-8,
 Ormeloxifene 40391-99-9 63619-84-1, Trioxifene 66376-36-1,
 Alendronate 75755-07-6, Piridronate 82413-20-5, Droxloxfene
 84449-90-1, Raloxifene 89778-26-7, Toremifene 105462-24-6
 114084-78-5, Ibandronate 116057-75-1, Idoxifene 118072-93-8,
 Zoledronate 121268-17-5 124351-85-5, Cimadronate 147764-85-0,
 BE-25327 172673-17-5 172673-18-6 172673-19-7 172673-20-0
 172673-21-1 172673-22-2 172822-01-4 175737-59-4 190791-29-8,
 CP-336156 200953-48-6 200954-82-1 200954-85-4 200954-87-6
 200955-96-0 200955-98-2 200957-56-8 200957-59-1 200957-88-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NK-1 receptor antagonist for treatment of or prevention of abnormal
 bone resorption)

IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hypercalcemia; NK-1 receptor antagonist for treatment of or prevention
 of abnormal bone resorption)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Chole, R; AMERICAN JOURNAL OF OTOLOGY 1998, V19(4), P521 MEDLINE
- (2) Ciba Geigy Ag; EP 0532456 A 1993 HCAPLUS
- (3) Donald, G; WO 9843639 A 1998 HCAPLUS
- (4) Fujisawa Pharmaceutical; EP 0443132 A 1991 HCAPLUS
- (5) Glaxo Group Ltd; WO 9508549 A 1995 HCAPLUS
- (6) Goto, T; CELL AND TISSUE RESEARCH 1998, V293(1), P87 HCAPLUS
- (7) Lilly Co Eli; WO 9514017 A 1995 HCAPLUS
- (8) Lilly Co Eli; EP 0693489 A 1996 HCAPLUS
- (9) Lilly Co Eli; EP 0761219 A 1997 HCAPLUS
- (10) MI, Y; WO 9637207 A 1996 HCAPLUS
- (11) Maccoss, M; WO 9523798 A 1995 HCAPLUS
- (12) Matthew, E; WO 9749710 A 1997 HCAPLUS
- (13) Merck & Co Inc; EP 0577394 A 1994 HCAPLUS
- (14) Merck Sharp & Dohme; WO 9518124 A 1995 HCAPLUS
- (15) Pfizer; EP 0436334 A 1991 HCAPLUS
- (16) Pfizer; WO 9217449 A 1992 HCAPLUS
- (17) Rhone Poulenc Rorer Sa; WO 9321155 A 1993 HCAPLUS
- (18) Rhone Poulenc Rorer Sa; WO 9416697 A 1994 HCAPLUS
- (19) Rhone Poulenc Rorer Sa; WO 9422822 A 1994 HCAPLUS
- (20) Sanofi Elf; EP 0591040 A 1994 HCAPLUS

IT 50-28-2, Estradiol, biological studies 53-39-4

, Oxandrolone 434-07-1, **Oxymetholone**
 10418-03-8, **Stanozolol** 17230-88-5,


Danazol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NK-1 receptor antagonist for treatment of or prevention of abnormal
 bone resorption)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 10 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 1998:87617 HCPLUS

DN 128:149982

ED Entered STN: 14 Feb 1998

TI Use of sex steroid function modulators to treat wounds and fibrotic disorders

IN Ferguson, Mark William James; Ashcroft, Gillian Sarah

PA Victoria University of Manchester, UK; Ferguson, Mark William James; Ashcroft, Gillian Sarah

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61K031-57; A61K031-135; A61K031-158; A61K031-105; A61K031-166; A61K031-122

CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803180	A2	19980129	WO 1997-GB1973	19970722 <--
	WO 9803180	A3	19980604		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,			

GN, ML, MR, NE, SN, TD, TG
 CA 2261263 AA 19980129 CA 1997-2261263 19970722 <--
 AU 9736288 A1 19980210 AU 1997-36288 19970722 <--
 AU 734465 B2 20010614
 ZA 9706480 A 19990122 ZA 1997-6480 19970722 <--
 EP 930876 A2 19990728 EP 1997-932922 19970722 <--
 EP 930876 B1 20041020
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2000515523 T2 20001121 JP 1998-506706 19970722 <--
 AT 279916 E 20041115 AT 1997-932922 19970722 <--
 EP 1506775 A1 20050216 EP 2004-77420 19970722 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 AU 755438 B2 20021212 AU 2001-54179 20010703 <--
 US 2002042401 A1 20020411 US 2001-939611 20010828 <--
 US 6696433 B2 20040224
 US 2004132701 A1 20040708 US 2003-740525 20031222 <--
 PRAI GB 1996-15348 A 19960722 <--
 GB 1997-1600 A 19970127 <--
 WO 1997-GB1973 W 19970722 <--
 EP 1997-932922 A3 19980129 <--
 US 1999-230226 B1 19990421 <--
 US 2001-939611 A1 20010828

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9803180	ICM	A61K031-565
	ICS	A61K031-57; A61K031-135; A61K031-158; A61K031-105; A61K031-166; A61K031-122
WO 9803180	ECLA	A61K031/05; A61K031/565T10; A61K031/565T5; A61K031/57; A61K031/57L; A61K031/57L5L; A61K031/57L5; A61K031/66D10; A61K031/138; A61K031/222; A61K031/565; A61K031/565F; A61K031/565L; A61K031/55L5; A61K031/565T; A61K031/565T10L <--
US 2002042401	ECLA	A61K031/05; A61K031/57L; A61K031/57L5; A61K031/57L5L; A61K031/58; A61K031/66D10; A61K031/138; A61K031/222; A61K031/565; A61K031/565F; A61K031/565L; A61K031/565L5; A61K031/565T; A61K031/565T5; A61K031/65T10; A61K031/565T10L; A61K031/57 <--

AB The present application relates to the use of compds. that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compds. for use in such treatments are steroid hormones and especially

the estrogens. Compns. containing the compds. of the invention are also claimed.

ST sex steroid function modulators wound healing; fibrosis treatment sex steroid function modulators

IT Drug delivery systems
 (aerosols; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgen receptors
 Estrogen receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (agonists and antagonists; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Progesterone receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (agonists; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Hormones, animal, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anabolic steroids; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiandrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiestrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiprogestins; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(conjugated; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(gels; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hormones; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(hydrogels; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(implants; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(liqs.; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Endocrine system

(modulators; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(ointments; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(ointments, creams; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phytoestrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(powder; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sex, precursors; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sex; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
 (solns., ophthalmic; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Hormones, animal, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (steroid; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Sex hormones
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (steroidal, precursors; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Sex hormones
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (steroidal; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
 Fibrosis
 Wound healing promoters
 (use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgens
 Estrogens
 Progestogens
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 9002-61-3, Chorionic gonadotrophin 9002-67-9, LH 9002-68-0, FSH
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modulators; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 50-27-1, Estriol 50-28-2, Estradiol, biological
 studies 50-41-9, Clomiphene citrate 53-43-0, DHEA 56-53-1,
 Stilbestrol 57-63-6, Ethynodiol diacetate 57-83-0, Progesterone,
 biological studies 72-33-3, Mestranol 84-17-3, Dienestrol 427-51-0,
 Cyproterone acetate 434-22-0, Nandrolone 481-97-0, Estrone
 3-sulfate 566-48-3, Formestane 651-48-9, DHEA sulfate 2624-43-3,
 Cyclofenil 4719-75-9 5630-53-5, Tibolone 7280-37-7, Piperazine
 estrone sulfate 10418-03-8, Stanozolol
 10540-29-1, Tamoxifen 13311-84-7, Flutamide 28014-46-2, Polyestradiol

phosphate 102676-31-3, Fadrozole hydrochloride 107868-30-4, Exemestane 120511-73-1, Anastrozole

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 51-98-9, Norethisterone acetate 57-85-2, Testosterone propionate 58-22-0, Testosterone 58-22-0D, Testosterone, esters 68-22-4, Norethisterone 71-58-9, Medroxyprogesterone acetate 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 315-37-7, Testosterone enanthate 432-60-0, Allylestrenol 521-18-6, Dihydrotestosterone 571-20-0 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone hexanoate 797-63-7, Levonorgestrel 1253-28-7, Gestronol hexanoate 1424-00-6, Mesterolone 1852-53-5 3836-23-5, Norethisterone enanthate 5949-44-0, Testosterone undecanoate 6533-00-2, Norgestrel 16320-04-0, Gestrinone 17230-88-5, Danazol 35189-28-7, Norgestimate 54024-22-5, Desogestrel 60282-87-3, Gestodene

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 50-28-2, Estradiol, biological studies

10418-03-8, Stanozolol


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of sex steroid function modulators to treat wounds and fibrotic disorders)

RN 50-28-2 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 17230-88-5, Danazol

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (use of sex steroid function modulators to treat wounds and fibrotic disorders)

RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 11 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 1994:622993 HCPLUS

DN 121:222993

ED Entered STN: 12 Nov 1994

TI Methods and formulations for use in treating oophorectomized women

IN Pike, Malcolm C.; Spicer, Darcy V.

PA University of Southern California, USA

SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-50

ICS A61K009-14

NCL 424426000

CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517 <--
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	US 5340584	A	19940823	US 1993-952513	19930201 <--
	CA 2162260	AA	19941124	CA 1994-2162260	19940512 <--
	WO 9426208	A1	19941124	WO 1994-US5262	19940512 <--

W: CA, FI, NO

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 EP 748191 A1 19961218 EP 1994-917357 19940512 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 NO 9504612 A 19960112 NO 1995-4612 19951115 <--
 PRAI US 1991-684612 A2 19910412 <--
 US 1993-952513 A2 19930201 <--
 WO 1992-US2973 W 19920410 <--
 US 1993-62886 A 19930517 <--
 WO 1994-US5262 W 19940512 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5340586	ICM	A61K009-50
	ICS	A61K009-14
	NCL	424426000
US 5340586	ECLA	A61K031/565+M; A61K031/57+M; A61K038/09; A61K038/09+M <--
US 5340584	ECLA	A61K038/09; A61K038/09+M <--
WO 9426208	ECLA	A61K009/16H6D4; A61K031/565+M; A61K031/57+M <--

AB **Compns.** and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amount of an estrogenic **composition** and an effective amount of an androgenic **composition**. The levels of estrogens and androgens employed are sufficient to reduce bone mineral d. loss and minimize other side effects observed after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in addnl. side effects.

ST oophorectomy estrogen androgen combined therapy

IT Ovariectomy
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Ovary, disease
(failure, oophorectomy symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, i.m., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, s.c., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(transdermal, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(vaginal, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-50-0, Estradiol benzoate 53-16-7, Estrone, biological studies 53-39-4, Oxandrolone 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 63-05-8, Androstenedione 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, Estradiol cypionate 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate 434-07-1, Oxymethalone 434-22-0, Nandrolone 514-68-1 517-09-9, Equilenin 521-10-8, Methandriol 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol


968-93-4, Testolactone 979-32-8, Estradiol valerate
 1240-04-6 7280-37-7, Piperazine estrone sulfate
 10418-03-8, Stanozolol 15183-37-6, Estetrol
 17230-88-5, Danazol 27651-95-2, Equilenin sulfate
 28014-46-2, Polystriadiol phosphate 147827-23-4, Pinestrol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ovarian failure symptoms treatment with estrogen and androgen
 combinations)

IT 50-28-2, Estradiol, biological studies 53-16-7
 , Estrone, biological studies 53-39-4,
 Oxandrolone 434-07-1, Oxymethalone 517-09-9,
 Equilenin 10418-03-8, Stanozolol 17230-88-5,
 Danazol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ovarian failure symptoms treatment with estrogen and androgen
 combinations)

RN 50-28-2 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
 4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 12 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 1994:622992 HCPLUS

DN 121:222992

ED Entered STN: 12 Nov 1994

TI Method and formulations for use in treating benign gynecological disorders

IN Pike, Malcolm C.; Spicer, Darcy V.

PA University of Southern California, USA

SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 952,513.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61F002-02

ICS A61F006-06; A61K037-38; A61K009-50

NCL 424426000

CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340585	A	19940823	US 1993-62883	19930517 <--
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	CA 2162261	AA	19941124	CA 1994-2162261	19940512 <--
	WO 9426207	A1	19941124	WO 1994-US5222	19940512 <--
	W: CA, FI, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	748190	A1	19961218	EP 1994-917349	19940512 <--
EP	748190	B1	20030730		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT	245992	E	20030815	AT 1994-917349	19940512 <--
PT	748190	T	20031231	PT 1994-917349	19940512 <--

ES 2204917	T3	20040501	ES 1994-917349	19940512 <--
NO 9504611	A	19960116	NO 1995-4611	19951115 <--
PRAI US 1991-684612	A2	19910412	<--	
US 1992-952513	A2	19921203	<--	
US 1993-62883	A	19930517	<--	
WO 1994-US5222	W	19940512	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 5340585	ICM	A61F002-02	
	ICS	A61F006-06; A61K037-38; A61K009-50	
	NCL	424426000	
US 5340585	ECLA	A61K038/09; A61K038/09+M	<--
WO 9426207	ECLA	A61K009/00M8B; A61K009/16H6D4; A61K038/09+M	<--

AB **Compns.** and methods which are effective to treat benign gynecol. disorders for extended periods of time in women in whom the risk of endometrial stimulation is minimized or absent are described, wherein an effective amount of a gonadotropin hormone-releasing hormone **comprn** . and an effective amount of an estrogenic **composition** are provided over a period of time, optionally with addition of an androgenic **composition** For example, both buserelin and **estradiol** were provided in the form of microspheres prepared from lactide-glycolide copolymer for i.m. administration over a 4 mo duration.

ST gonadotropin releasing hormone estrogen gynecol disorder; buserelin **estradiol** premenstrual syndrome

IT Ovary, neoplasm
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Ovarian cycle
(disorder, premenstrual syndrome, GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(injections, i.m., GnRH **composition** and estrogenic **comprn** . combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(injections, s.c., GnRH **composition** and estrogenic **comprn** . combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(transdermal, GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(vaginal, GnRH **composition** and estrogenic **comprn** . combination for treatment of benign gynecol. disorders)

IT 50-27-1, **Estriol** 50-28-2, **Estradiol**, biological studies 50-50-0, **Estradiol** benzoate 53-16-7, **Estrone**, biological studies 53-39-4, **Oxandrolone** 56-53-1, **Diethylstilbestrol** 57-63-6, **Ethinyl estradiol** 57-83-0, **Progesterone**, biological studies 57-85-2, **Testosterone** propionate 58-18-4, **Methyltestosterone** 58-19-5, **Dromostanolone** 58-20-8, **Testosterone cypionate** 58-22-0, **Testosterone** 62-90-8, **Nandrolone phenpropionate** 63-05-8, **Androstenedione** 72-33-3, **Mestranol** 152-43-2, **Quinestrol** 313-06-4, **Estradiol cypionate** 315-37-7, **Testosterone enanthate** 360-70-3, **Nandrolone decanoate** 434-07-1, **Oxymethalone** 514-68-1 517-09-9, **Equilenin** 521-10-8, **Methandriol** 521-18-6, **Dihydrotestosterone** 965-90-2, **Ethylestrenol** 968-93-4, **Testolactone** 979-32-8, **Estradiol valerate** 1240-04-6 7280-37-7, **Piperazine estrone sulfate** 9034-40-6, **Gonadotropin releasing hormone** 10418-03-8, **Stanozolol**

15183-37-6, Estetrol 17230-88-5, Danazol 27651-95-2,
 Equilenin sulfate 28014-46-2, Polyestradiol phosphate 33515-09-2,
 Gonadorelin 57773-63-4, Decapeptyl 57773-65-6, Deslorelin
 57982-77-1, Buserelin 65807-02-5, Goserelin 74381-53-6, Leuprolide
 acetate 76712-82-8, Histrelin 76932-56-4, Nafarelin 147827-23-4,
 Pinestrol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GnRH composition and estrogenic composition combination for
 treatment of benign gynecol. disorders)

IT 50-28-2, Estradiol, biological studies 53-16-7

, Estrone, biological studies 53-39-4,

Oxandrolone 434-07-1, Oxymethalone 517-09-9,

Equilenin 10418-03-8, Stanazolol 17230-88-5,


Danazol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GnRH composition and estrogenic composition combination for
 treatment of benign gynecol. disorders)

RN 50-28-2 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
 4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 517-09-9 HCPLUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 13 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

AN 1993:198196 HCPLUS

DN 118:198196

ED Entered STN: 14 May 1993

TI Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders

IN Spicer, Darcy Vernon; Pike, Malcolm Cecil

PA University of Southern California, USA

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-14

ICS A61F002-02

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218107	A1	19921029	WO 1992-US2973	19920410 <--
	W: CA, FI, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US	5211952	A	19930518	US 1991-684612	19910412 <--
CA	2084891	AA	19921013	CA 1992-2084891	19920410 <--
CA	2084891	C	19990105		
EP	538443	A1	19930428	EP 1992-910686	19920410 <--
EP	538443	B1	19971001		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AT	158717	E	19971015	AT 1992-910686	19920410 <--
ES	2109995	T3	19980201	ES 1992-910686	19920410 <--

NO 9204755	A	19930209	NO 1992-4755	19921209 <--
FI 104789	B1	20000414	FI 1992-5652	19921211 <--
US 5340584	A	19940823	US 1993-952513	19930201 <--
PRAI US 1991-684612	A2	19910412	<--	
WO 1992-US2973	W	19920410	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES		
WO 9218107	ICM	A61K009-14		
	ICS	A61F002-02		
US 5340584	ECLA	A61K038/09; A61K038/09+M <--		
AB	Slow-release compns. for inhibiting conception and treating benign gynecol. disorders contain a gonadotropin hormone releasing hormone (GnRH), an estrogen to be released first, in addition to a progestogen and, optionally, an androgen. An. i.m. delivery system for administration over 4 mo contains buserelin, estradiol, and progesterone, such that the amount of GnRH is sufficient to suppress LH and FSH secretion during the entire period of administration. Both buserelin and estradiol are in the form of glycolide-lactide microspheres.			
ST	contraceptive slow release; gonadotropin hormone releasing hormone contraceptive; estrogen contraceptive; progestogen contraceptive			
IT	Androgens Estrogens Progesterogens RL: BIOL (Biological study) (contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormones and)			
IT	Drug bioavailability (of contraceptive compds., from slow-release pharmaceuticals)			
IT	Contraceptives (slow-release, gonadotropin hormone releasing hormones and estrogens and progestogens and androgens in)			
IT	Pharmaceutical dosage forms (slow-release, contraceptives, gonadotropin hormone releasing hormones in)			
IT	50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-50-0, Estradiol benzoate 53-16-7, Estrone, biological studies 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl estradiol 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, Estradiol cypionate 517-09-9 979-32-8, Estradiol valerate 1240-04-6 7280-37-7, Estropipate 15183-37-6, Estetrol 27651-95-2 28014-46-2, Polyestradiol phosphate 29130-44-7 147827-23-4, Pinestrol RL: BIOL (Biological study) (contraceptive slow-release compns. containing gonadotropin hormone releasing hormones and, as estrogen)			
IT	33515-09-2, Gonadorelin 55599-59-2 57773-63-4, Decapeptyl 57773-65-6, Deslorelin 57982-77-1, Buserelin 65807-02-5, Goserelin 74381-53-6, Leuprolide acetate 76712-82-8 76932-56-4, Nafarelin RL: BIOL (Biological study) (contraceptive slow-release pharmaceuticals containing)			
IT	53-39-4, Oxandrolone 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate 434-07-1 521-10-8, Methandriol 521-12-0 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4, Testolactone 10418-03-8, Stanozolol 17230-88-5, Danazol RL: BIOL (Biological study) (contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormone and, as androgen)			
IT	51-98-9 68-22-4, Norethindrone 68-23-5, Norethynodrel 71-58-9, Medroxyprogesterone acetate 152-62-5, Dydrogesterone 297-76-7,			

Ethynodiol diacetate 595-33-5, Megestrol acetate 630-56-8 6533-00-2,
 Norgestrel 57-83-0P, Progesterone, preparation
 RL: BIOL (Biological study)

(contraceptive slow-release pharmaceuticals containing gonadotropin hormone
 releasing hormone and, as progestogen)


IT 50-28-2, Estradiol, biological studies 53-16-7
 , Estrone, biological studies 517-09-9

RL: BIOL (Biological study)
 (contraceptive slow-release compns. containing gonadotropin
 hormone releasing hormones and, as estrogen)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 517-09-9 HCAPIUS

CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 53-39-4, Oxandrolone 434-07-1
 10418-03-8, Stanozolol 17230-88-5,

Danazol


RL: BIOL (Biological study)

(contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormone and, as androgen)

RN 53-39-4 HCPLUS

CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434-07-1 HCPLUS

CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 10418-03-8 HCPLUS

CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5 α ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 17230-88-5 HCPLUS

CN Pregna-2,4-dien-20-yne[2,3-d]isoxazol-17-ol, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> => fil medline
FILE 'MEDLINE' ENTERED AT 15:52:50 ON 23 FEB 2005

FILE LAST UPDATED: 22 FEB 2005 (20050222/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

Warning: The search L-number/HUMAN limit is missing from records indexed with the new 2005 MeSH (records added since December 19, 2004). Until this is corrected, include HUMANS/CT and 20041219-20051231/ED in searches to limit results to humans for this time period.

OLD MEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot 172

L72 ANSWER 1 OF 9 MEDLINE on STN

AN 94297384 MEDLINE

AN 94297384 MEDLINE
DN PubMed ID: 8025411

DN PubMed ID: 8025411
TI Change in speaking fundamental frequency in hormone-treated patients with Turner's syndrome--a longitudinal study of four cases

All Turner's syndrome--a longitudinal study of Andersson-Wallgren G, Albertsson-Wiklund K

AS Andersson-Wahlberg G, Albertsson-Wiklund K
CS Department of Logopedics and Phoniatrics, University of Göteborg, Sweden

CS Department of Logopedics and Phoniatrics, University of Göteborg
SO Acta paediatrica (Oslo, Norway) 1982, (1984 April) 83, (1), 153-5

SO *Acta paediatrica (Oslo, Norway : 1992)*,
Journal code: 820E868 ISSN: 0803-5353

Journal
of
Norway

CY Norway
DT Journal Article (JOURNAL ARTICLE)

DT
LA

LA English
ES Priority Journals

FS PF18P1
FM 188408

ED Entered STN: 19940818

Last Updated on STN: 18840818

Last updated on SIN: 1994
Entered Medline: 18840810

AB Entered Medline: 19940810
Change in speaking fundamental frequency for four hormone-treated girls with Turner's syndrome was registered using two computerized analysis methods for a period of four years. The girls were treated with human

growth hormone, oxandrolone and ethinyl estradiol. The overall pattern for three of the girls was a distinct decline in speaking fundamental frequency during the first year, while for the fourth patient the pattern of change was more complicated. For all four girls, the final pitch level was within the normal range for adult women. It is important that voice effects are taken into account in the hormonal treatment of Turner's syndrome and that patients are informed of the changes to be expected.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't Adolescent Child

Drug Therapy, Combination

*Ethinyl Estradiol: AD, administration & dosage

*Growth Hormone: AD, administration & dosage

Longitudinal Studies

*Oxandrolone: AD, administration & dosage

*Turner Syndrome: DT, drug therapy

*Turner Syndrome: PP, physiopathology

*Voice Quality: DE, drug effects

RN 53-39-4 (Oxandrolone); 57-63-6 (Ethinyl Estradiol); 9002-72-6 (Growth Hormone)

L72 ANSWER 2 OF 9 MEDLINE on STN

AN 92058173 MEDLINE

DN PubMed ID: 1950723

TI Alternative treatments in oral postcoital contraception: interim results.

AU Webb A M

CS University of Manchester, Department of Obstetrics and Gynaecology, UK.

SO Advances in contraception : official journal of the Society for the Advancement of Contraception, (1991 Jun-Sep) 7 (2-3) 271-9.

Journal code: 8607435. ISSN: 0267-4874.

CY Netherlands

DT (CLINICAL TRIAL)

Journal; Article; (JOURNAL ARTICLE)

(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

EM 199111

ED Entered STN: 19920124

Last Updated on STN: 19920124

Entered Medline: 19911129

AB The study compares the effectiveness and acceptability of three regimes of postcoital contraception: 1) ethinylestradiol 100 micrograms/levonorgestrel 500 micrograms repeated after 12 hours (Yuzpe method); 2) danazol 600 mg repeated after 12 hours; and 3) RU486 600 mg single dose. Between 1 April 1990 and 15 October 1990, 215 women were selected and randomly allocated to the three treatment groups. One hundred and sixty eight were fully followed up, 35 ongoing and 8 lost to follow-up. All women had regular cycles and were aged 16-45 years. All treatments were given within 72 hours of unprotected intercourse and follow-up was until normal menstruation or diagnosis of pregnancy. beta-HCG was measured quantitatively where there was a suspicion of pregnancy. The data obtained show similar failure rates (Yuzpe 1/57, danazol 2/57, RU486 1/54) but more side-effects in the Yuzpe group (nausea 74.1%, vomiting 22.4%, breast tenderness 22.4%) than in the other two (danazol: nausea 31.6%, vomiting 3.5%, breast tenderness 19.3%) and (RU486: nausea 36.4%, vomiting 3.6%, breast tenderness 23.6%). There was one apparent allergic reaction in the danazol group. RU486 caused greater cycle disturbance, prolonging the cycle considerably. Initial results suggest that danazol and RU486 may be much more acceptable methods of postcoital contraception due to reduced side-effects and, in the latter case, single dose. Although numbers are small at present, the effectiveness of the newer methods appear similar to Yuzpe.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't
 Abortifacient Agents: AE, adverse effects
 Abortifacient Agents: ST, standards
 Adolescent
 Adult
 *Contraceptives, Oral: TU, therapeutic use
 *Contraceptives, Postcoital: ST, standards
 Danazol: AE, adverse effects
 Danazol: ST, standards
 Drug Combinations
 Ethinyl Estradiol: AE, adverse effects
 Ethinyl Estradiol: ST, standards
 Levonorgestrel: AE, adverse effects
 Levonorgestrel: ST, standards
 Middle Aged
 Mifepristone: AE, adverse effects
 Mifepristone: ST, standards
 Time Factors

RN 17230-88-5 (Danazol); 57-63-6 (Ethinyl Estradiol);
 797-63-7 (Levonorgestrel); 84371-65-3 (Mifepristone)

CN 0 (Abortifacient Agents); 0 (Contraceptives, Oral); 0 (Contraceptives, Postcoital); 0 (Drug Combinations)

L72 ANSWER 3 OF 9 MEDLINE on STN

AN 91301363 MEDLINE

DN PubMed ID: 1830018

TI Endometrial patterns during **danazol** and cyproterone acetate treatment for endometriosis: structural and ultrastructural study.

AU Marchini M; Fedele L; Bianchi S; Arcaini L; Brioschi D; Di Nola G

CS 1st Department of Obstetrics and Gynecology, University of Milan, Italy.

SO European journal of obstetrics, gynecology, and reproductive biology, (1991 Jul 1) 40 (2) 137-43.

Journal code: 0375672. ISSN: 0301-2115.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199108

ED Entered STN: 19910908

Last Updated on STN: 19910908

Entered Medline: 19910822

AB We studied the endometrial structure and ultrastructure in serial biopsies from 16 patients with endometriosis treated with **danazol** (n = 9) or the combination cyproterone acetate plus **ethinyl estradiol** (n = 7) for 6 months. Biopsies were performed before and at 3 and 6 months of treatment. The material obtained was studied by light (LM), scanning (SEM) and transmission electron microscopy (TEM). A morphometric analysis was performed evaluating three morphometric and three stereologic indices. The results indicate that **danazol** had a progestational effect on endometrial glands and stroma, associated with a marked hypotrophy of the mucosa. The cyproterone acetate/**ethinyl estradiol** combination induced progressive atrophy of the endometrium with an increase in the stromal component and a reduction of glandular tissue.

CT Check Tags: Comparative Study; Female; Human

Adult

Biopsy

Cyproterone: AD, administration & dosage

*Cyproterone: AA, analogs & derivatives

Cyproterone: TU, therapeutic use

Cyproterone Acetate

*Danazol: TU, therapeutic use

Drug Combinations

*Endometriosis: DT, drug therapy

Endometriosis: PA, pathology
 Endometrium: DE, drug effects
 *Endometrium: PA, pathology
 Endometrium: UL, ultrastructure
 Estradiol: BL, blood
 Ethinyl Estradiol: AD, administration & dosage
 *Ethinyl Estradiol: AA, analogs & derivatives
 Ethinyl Estradiol: TU, therapeutic use

Follicle Stimulating Hormone: BL, blood
 Luteinizing Hormone: BL, blood

RN 108646-70-4 (ethinyl estriol); 17230-88-5 (Danazol); 2098-66-0
 (Cyproterone); 427-51-0 (Cyproterone Acetate); 50-28-2 (Estradiol)
 ; 57-63-6 (Ethinyl Estradiol); 9002-67-9 (Luteinizing Hormone);
 9002-68-0 (Follicle Stimulating Hormone)

CN 0 (Drug Combinations)

L72 ANSWER 4 OF 9 MEDLINE on STN

AN 91032502 MEDLINE

DN PubMed ID: 2227068

TI Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two **danazol** regimens.

AU Zuliani G; Colombo U F; Molla R

CS AIECS Family Planning Centre, Milan, Italy.

SO European journal of obstetrics, gynecology, and reproductive biology, (1990 Dec) 37 (3) 253-60.

Journal code: 0375672. ISSN: 0301-2115.

Report No.: PIP-064397; POP-00199185.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Population

EM 199012

ED Entered STN: 19910208

Last Updated on STN: 20021101

Entered Medline: 19901212

AB The ethinylestradiol-norgestrel combination (EE-NG) for postcoital contraception, as described by Yuzpe, has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects a new approach using **danazol** was proposed, but the efficacy and acceptability of this treatment have not yet been tested in large studies. In a 5-year period at the AIECS Family Planning Centre in Milan we treated 2448 women requesting postcoital contraception using Yuzpe's regimen and two **danazol** regimens (800 mg/1200 mg). The patients' acceptability for **danazol** treatment was higher than for Yuzpe's regimen due to fewer, milder and shorter side effects. Nine pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%) and 6 in the 1200 mg group (0.82%). Our study shows a statistically significant efficacy against expected pregnancy rates both with Yuzpe's regimen and with **danazol**. The 1200 mg **danazol** treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception. The ethinyl estradiol-norgestrel combination (EE-NG) for postcoital contraception as described by Yuzpe has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects, a new approach using **danazol** was proposed, but the efficacy and acceptability of this treatment has not yet been put to the test in larger groups. In a 5-year period at the AIECS Family Planning Center in Milan, the authors treated 2448 women requesting postcoital contraceptives using Yuzpe's regimen and 2 **danazol** regimens (800 mg/1200 mg). The **danazol** treatment met with a greater measure of patient acceptability than did Yuzpe's regimen, due mainly to the smaller number of side effects. 9 pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%), and 6 in the 1200

mg group (0.82%). This study shows a statistically significant efficacy against expected pregnancy rates, both with Yuzpe's regimen and with **danazol**. The 1200 mg **danazol** treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception.

author's modified

ST Age Distribution; Age Factors; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents, Estrogen--administration and dosage; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--administration and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administration and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administration and dosage; Contraceptive Agents--side effects; Contraceptive Usage; Data Collection; Demographic Factors; Developed Countries; Diseases; Ethinyl **Estradiol**--administration and dosage; Ethinyl **Estradiol**--side effects; Europe; Family Planning; Fertility; Fertility Control, Postcoital; Fertility Measurements; Follow-up Studies; Italy; Mediterranean Countries; Method Acceptability; Norgestrel--administration and dosage; Norgestrel--side effects; Parity; Population; Population Characteristics; Population Dynamics; Pregnancy Rate; Research Methodology; Signs And Symptoms; Southern Europe; Studies

CT Check Tags: Comparative Study; Female; Human
 Adolescent
 Adult
 *Contraceptives, Postcoital, Hormonal
 Contraceptives, Postcoital, Hormonal: AE, adverse effects
 ***Danazol: AD, administration & dosage**
 Drug Administration Schedule
 Drug Combinations
 ***Ethinyl Estradiol: AD, administration & dosage**
 *Norgestrel: AD, administration & dosage
 Pregnancy

RN 17230-88-5 (**Danazol**); 57-63-6 (**Ethinyl Estradiol**);
 6533-00-2 (**Norgestrel**)

CN 0 (Contraceptives, Postcoital, Hormonal); 0 (Drug Combinations)

L72 ANSWER 5 OF 9 MEDLINE on STN
 AN 90093148 MEDLINE
 DN PubMed ID: 2689306
 TI [Hormone therapy of endometriosis].
 Hormontherapie der Endometriose.
 AU Distler W
 CS Universitäts-Frauenklinik Düsseldorf.
 SO Der Gynakologe, (1989 Oct) 22 (5) 294-301. Ref: 57
 Journal code: 0410275. ISSN: 0017-5994.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA German
 FS Priority Journals
 EM 199002
 ED Entered STN: 19900328
 Last Updated on STN: 19900328
 Entered Medline: 19900202
 CT Check Tags: Female; Human
 ***Danazol: TU, therapeutic use**
 ***Drug Therapy, Combination**
 ***Endometriosis: DT, drug therapy**
 ***Estradiol Congeners: TU, therapeutic use**
 ***Genital Neoplasms, Female: DT, drug therapy**
 ***Hormones: TU, therapeutic use**

Pituitary Hormone-Releasing Hormones: TU, therapeutic use
 Progesterone Congeners: TU, therapeutic use
 RN 17230-88-5 (Danazol)
 CN 0 (Estradiol Congeners); 0 (Hormones); 0 (Pituitary
 Hormone-Releasing Hormones); 0 (Progesterone Congeners)

L72 ANSWER 6 OF 9 MEDLINE on STN
 AN 90052449 MEDLINE
 DN PubMed ID: 2816362
 TI Effect of recombinant human growth hormone therapy on bone and clinical
 parameters in girls with Turner's syndrome. The Spanish Collaborative
 Group.
 AU Ferrandez A; Mayayo E; Arnal J M; Garcia C; Bunuel C; Lasarte J J; Anton
 R; Puyuelo P
 CS Endocrine Unit, Children's Hospital, Zaragoza, Spain.
 SO Acta paediatrica Scandinavica. Supplement, (1989) 356 87-91;
 discussion 92.
 Journal code: 0173166. ISSN: 0300-8843.
 CY Sweden
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198912
 ED Entered STN: 19900328
 Last Updated on STN: 19900328
 Entered Medline: 19891205
 AB Forty-eight girls with Turner's syndrome were assigned to one of three
 treatments; recombinant human growth hormone (rhGH) alone, rhGH plus
 oxandrolone, and rhGH plus ethinyloestradiol. Treatment with rhGH
 alone or in combination with oxandrolone induced catch-up
 growth. Older girls treated with rhGH plus ethinyloestradiol showed less
 marked improvement. The gain in height was associated with a gain in bone
 diameter and cortical thickness (reflecting increased bone mass). There
 was a rapid loss of subcutaneous fat. These effects of growth hormone are
 similar to those observed in patients with growth hormone deficiency.
 CT Check Tags: Female; Human
 Adolescent
 *Bone Development: DE, drug effects
 Child
 Child, Preschool
 Drug Therapy, Combination
 Ethynodiol: TU, therapeutic use
 *Growth Disorders: DT, drug therapy
 *Growth Hormone: TU, therapeutic use
 Oxandrolone: TU, therapeutic use
 Recombinant Proteins
 Skinfold Thickness
 *Turner Syndrome: CO, complications
 RN 53-39-4 (Oxandrolone); 57-63-6 (Ethynodiol);
 9002-72-6 (Growth Hormone)
 CN 0 (Recombinant Proteins)

L72 ANSWER 7 OF 9 MEDLINE on STN
 AN 89239508 MEDLINE
 DN PubMed ID: 2654820
 TI [The current treatment concept of Turner syndrome].
 Aktuelles Behandlungskonzept des Turner-Syndroms.
 AU Blumel P; Stogmann W
 CS Gottfried von Preyersches Kinderspital der Stadt Wien.
 SO Padiatrie und Padologie, (1989) 24 (1) 81-9. Ref: 36
 Journal code: 0022370. ISSN: 0030-9338.
 CY Austria
 DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
 (REVIEW, TUTORIAL)

LA German
 FS Priority Journals
 EM 198906
 ED Entered STN: 19900306
 Last Updated on STN: 19900306
 Entered Medline: 19890609

AB Turner's Syndrome (XO Karyotype or XO/XX mosaicism) affects 1 in 2500 females. It results in short stature (mean adult height is about 146 cm), infertility and the lack of secondary sexual characteristics. Hormone replacement therapy to develop secondary sexual characteristics has been used for years whereas several growth promoting agents undergo clinical trials at the moment. Our current management for patients with Turner's Syndrome includes the induction of puberty at a bone age of 11 to 12 years with low dose oestradiol and the application of biosynthetic human growth hormone (hGH) when growth velocity falls below the normal range. In our group of previously untreated patients (4.6-14 years) one year results of hGH application (12-18 IU/m2/week 7 equal doses sc/week) show a clear improvement of growth velocity (3.43 + 0.44 cm/year before therapy versus 6.2 + 1.14 cm/year after the first year of treatment, p less than 0.001). The growth promoting effect of hGH therapy might further be improved by the combination with anabolic steroids like oxandrolon.

CT Check Tags: Female; Human
 Adolescent
 Body Height: DE, drug effects
 Child
 Drug Therapy, Combination
 English Abstract
 Estradiol: AD, administration & dosage
 Ethinyl Estradiol: AD, administration & dosage
 Growth Hormone: AD, administration & dosage
 Oxandrolone: AD, administration & dosage
 *Turner Syndrome: TH, therapy

RN 50-28-2 (Estradiol); 53-39-4 (Oxandrolone);
 57-63-6 (Ethinyl Estradiol); 9002-72-6 (Growth Hormone)

L72 ANSWER 8 OF 9 MEDLINE on STN
 AN 86005552 MEDLINE
 DN PubMed ID: 3850029
 TI [Endometriosis].
 Endometrioz.
 AU Kiriushchenkov A P
 SO Fel'dsher i akusherka, (1985 Jul) 50 (7) 14-21.
 Journal code: 16930040R. ISSN: 0014-9772.
 CY USSR
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Nursing Journals
 EM 198511
 ED Entered STN: 19900321
 Last Updated on STN: 19900321
 Entered Medline: 19851115

CT Check Tags: Female; Human
 *Cervix Neoplasms: DI, diagnosis
 Cervix Neoplasms: TH, therapy
 Danazol: TU, therapeutic use
 Drug Combinations
 *Endometriosis: DI, diagnosis
 Endometriosis: TH, therapy
 English Abstract
 Estradiol Congeners: TU, therapeutic use
 *Ovarian Neoplasms: DI, diagnosis

Ovarian Neoplasms: TH, therapy
 RN 17230-88-5 (Danazol)
 CN 0 (Drug Combinations); 0 (Estradiol Congeners)

L72 ANSWER 9 OF 9 MEDLINE on STN
 AN 84263633 MEDLINE
 DN PubMed ID: 6146575
 TI Open forum: Diagnosis and treatment of endometriosis.
 AU Anonymous
 SO International journal of fertility, (1984) 29 (1) 1-9.
 Journal code: 0374717. ISSN: 0020-725X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198409
 ED Entered STN: 19900320
 Last Updated on STN: 19950206
 Entered Medline: 19840907
 CT Check Tags: Female; Human
 Danazol: TU, therapeutic use
 Drug Therapy, Combination
 *Endometriosis
 Endometriosis: DI, diagnosis
 Endometriosis: DT, drug therapy
 Endometriosis: SU, surgery
 *Estradiol Congeners: TU, therapeutic use
 Hysterectomy
 Laparoscopy
 Medroxyprogesterone: TU, therapeutic use
 *Pelvic Neoplasms
 Pelvic Neoplasms: DI, diagnosis
 Pelvic Neoplasms: DT, drug therapy
 Pelvic Neoplasms: SU, surgery
 *Progesterone Congeners: TU, therapeutic use
 RN 17230-88-5 (Danazol); 520-85-4 (Medroxyprogesterone)
 CN 0 (Estradiol Congeners); 0 (Progesterone Congeners)

=> d his

(FILE 'HOME' ENTERED AT 15:05:26 ON 23 FEB 2005)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:05:33 ON 23 FEB 2005

L1 1 S US20020151530/PN OR (US2001-029424# OR WO2001-US51045 OR US20
 E LEONARD T/AU
 L2 54 S E3,E15,E24,E25,E30
 E WALDON R/AU
 L3 5 S E4,E6
 E ENDEAVOR/PA,CS
 L4 23 S E3-E17

FILE 'REGISTRY' ENTERED AT 15:13:15 ON 23 FEB 2005

L5 1 S 53-16-7
 L6 1 S 474-86-2
 L7 1 S 474-87-3
 L8 1 S 57-91-0
 L9 1 S 3563-27-7
 L10 1 S 651-55-8
 L11 1 S 50-28-2
 L12 1 S 517-09-9
 L13 1 S 6639-99-2

L14 1 S 1423-97-8
 L15 10 S L5-L14
 SEL RN
 L16 185 S E1-E10/CRN
 L17 1 S 53-39-4
 L18 1 S 434-07-1
 L19 1 S 10418-03-8
 L20 1 S 17230-88-5
 L21 4 S L17-L20
 SEL RN
 L22 13 S E11-E14/CRN
 L23 0 S L16 AND L22

FILE 'HCAPLUS' ENTERED AT 15:17:00 ON 23 FEB 2005

L24 58199 S L15
 L25 31491 S ESTRONE OR EQUILIN OR DELTA 8 9 DEHYDROESTERONE OR (17A OR 17
 L26 73257 S ESTRADIOL
 L27 85 S (17A OR 17ALPHA OR 17B OR 17BETA OR 17() (ALPHA OR BETA)) ()OES
 L28 81641 S L24-L27
 L29 1451 S L21
 L30 1378 S OXANDROLONE OR OXYMETHOLONE OR STANOZOLOL OR DANAZOL
 L31 1614 S L29, L30
 L32 316 S L28 AND L31
 L33 268 S L32 AND (PD<=20001222 OR PRD<=20001222 OR AD<=20001222 OR PY<
 E HORMONE REPLACEMENT THERAPY/CT
 E E3+ALL
 L34 3632 S E4
 L35 5515 S E4-E6/BI
 L36 3660 S HRT
 L37 5 S L33 AND L34-L36
 E MENOPAUSE/CT
 L38 9435 S E3-E12
 E E3+ALL
 L39 12388 S E4,E5/BI
 L40 18481 S ?MENOPAUS?
 L41 16 S L33 AND L38-L40
 L42 18 S L37, L41
 L43 5 S L1-L4 AND L32
 L44 89 S L33 AND (UTERUS OR UTERIN? OR VAGINA OR VAGINAL)
 E SEX/CT
 E E3+ALL
 L45 6 S L33 AND E2+NT
 E E11+ALL
 L46 7 S L33 AND E3+OLD, NT
 L47 31 S L42, L43, L45, L46
 L48 26 S L47 NOT L43
 L49 19 S L48 AND L24 AND L29
 SEL DN AN 6 7
 L50 2 S L49 AND E1-E6
 L51 17 S L49 NOT L50
 SEL DN AN 2 5 6
 L52 3 S L51 AND E7-E15
 L53 7 S L47 NOT L49, L43
 L54 79 S L44 NOT L43, L45-L53
 SEL DN AN 26
 L55 1 S L54 AND E16-E18
 L56 9 S L43, L52, L55
 L57 40 S L33 AND COMPOSITION
 L58 35 S L57 NOT L56
 SEL DN AN 6 8 11 15
 L59 4 S L58 AND E19-E30
 L60 13 S L56, L59 AND L1-L4, L24-L59

FILE 'REGISTRY' ENTERED AT 15:44:50 ON 23 FEB 2005

FILE 'HCAPLUS' ENTERED AT 15:46:15 ON 23 FEB 2005

FILE 'MEDLINE' ENTERED AT 15:46:59 ON 23 FEB 2005

L61 59194 S L15
L62 79897 S L25 OR L26 OR L27
L63 137 S EQUILENIN
L64 79939 S L61-L63
L65 2900 S L21
L66 3496 S L30
L67 322 S L64 AND L65,L66
L68 309 S L67 AND PY<=2000
E DRUG COMBINATION/CT
E E6+ALL
L69 39026 S E3
E DRUG THERAPY, COMBINATION/CT
E E3+ALL
L70 79604 S E4
E E5+ALL
L71 17 S L68 AND L69,L70
SEL DN AN 4 6 7 8 9 10 13 14 16
L72 9 S L71 AND E1-E18
E HORMONE REPLACEMENT THERAPY/CT
E E3+ALL
L73 3127 S E4
L74 9250 S E12
L75 1 S L68 AND L73,L74

FILE 'MEDLINE' ENTERED AT 15:52:50 ON 23 FEB 2005

=>